Page last updated: 2024-10-16

adenine and Hepatitis B

adenine has been researched along with Hepatitis B in 382 studies

Hepatitis B: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients."9.41Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023)
"Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes."9.2796 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. ( Agarwal, K; Ahn, SH; Bae, H; Bhardwaj, N; Brunetto, M; Buti, M; Cathcart, AL; Çelen, MK; Chan, HLY; Chuang, WL; Flaherty, JF; Fung, S; Furusyo, N; Gaggar, A; Gane, EJ; Izumi, N; Janssen, HLA; Lau, AH; Lim, YS; Lin, L; Mani Subramanian, G; Marcellin, P; Pan, CQ; Seto, WK; Shalimar, D; Sharma, M; Suri, V; Trinh, H; Yoon, KT, 2018)
"Adefovir, a nucleotide analog developed by John Martin, was a major breakthrough in the treatment of chronic Hepatitis B."9.22Adefovir for lamivudine-resistant hepatitis B. ( Dieterich, D; Roediger, R; Smyth, EK, 2022)
"Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B."9.22Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016)
"To compare efficacy of combined lamivudine (LAM) and adefovir dipivoxil (ADV) therapy with that of entecavir (ETV) monotherapy for hepatitis B virus (HBV)-related decompensated liver cirrhosis."9.17De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. ( Chen, JY; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2013)
" At month 24, virological response rate [hepatitis B virus (HBV) DNA <60 IU/ml] was higher in the adefovir-lamivudine combination group compared with entecavir group (56."9.17Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Um, SH; Yim, HJ; Yoon, EL, 2013)
"Adefovir dipivoxil (ADV) is effective in lamivudine (LAM)-resistant hepatitis B e antigen-negative (HBeAg(-)) chronic hepatitis B (CHB)."9.14Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. ( Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Koumaras, H; Koumerkeridis, G; Mpoumponaris, A; Panderi, A; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, TG, 2010)
"To investigate the efficacy and safety of adefovir dipivoxil (ADV) in treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis."9.13[Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis]. ( Chen, YS; Jin, ZJ; Li, DF; Qiao, LM; Zhou, J, 2008)
"The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations."9.13Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. ( Calabresi, A; Carosi, G; Cologni, G; Costarelli, S; Lapadula, G; Puoti, M; Quiros-Roldan, E; Tirelli, V; Torti, C; Zaltron, S, 2008)
"Adefovir dipivoxil (ADV) is a nucleotide analogue that is known to be effective for lamivudine-resistant hepatitis B virus (HBV) mutants as well as wild-type HBV."9.12Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. ( Cho, YS; Kim, DH; Kim, DY; Kim, HJ; Lee, CK; Park, BK; Park, IS; Suh, JH; Won, SY, 2007)
"Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively."9.12Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. ( Arterburn, S; Borroto-Esoda, K; Brosgart, C; Chuck, S; Colombo, M; Hadziyannis, S; Lai, CL; Neuhaus, P; Samuel, D; Schiff, E; Terrault, N; Tillmann, H; Villeneuve, JP; Zeuzem, S, 2007)
"Low-dose TDF monotherapy can control HBV viremia for an extended period of time without the emergence of resistance and is more potent than adefovir at the standard dosage."9.12Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. ( Colombo, S; Del Poggio, P; Jamoletti, C; Oggionni, M; Puhalo, V; Zaccanelli, M, 2007)
"Adefovir monotherapy is an established treatment modality for lamivudine-experienced patients with chronic hepatitis B, but it carries a significant risk of resistance in the long term."9.12Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. ( Colombo, M; Iavarone, M; Lampertico, P; Manenti, E; Sablon, E; Viganò, M, 2007)
"Phase II and III clinical trials of adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B have shown that this hepadnavirus polymerase inhibitor is well tolerated and effectively suppresses hepatitis B virus (HBV) replication."9.11Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. ( Cinquin, K; Marcellin, P; Maynard, M; Pol, S; Trépo, C; Werle, B; Zoulim, F, 2004)
"We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir."9.11Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. ( Bani-Sadr, F; Molina, JM; Palmer, P; Scieux, C, 2004)
"The purpose of this prospective study was to evaluate the efficacy and safety of adefovir dipivoxil with or without ongoing lamivudine in decompensated lamivudine-resistant chronic hepatitis B patients."9.11Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. ( Choi, WB; Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Suh, DJ, 2005)
"Randomised clinical trials addressing benefits and harms of lamivudine or adefovir dipivoxil alone or in combination with hepatitis B immunoglobulins (HBIg) for preventing recurrent HBV infection in patients who are liver transplanted due to HBV infection with or without hepatocellular carcinoma."8.86Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. ( Guy, DG; Katz, LH; Paul, M; Tur-Kaspa, R, 2010)
"Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects."8.12Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide ( Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML, 2022)
"Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking."8.12Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. ( Chen, ZM; Cui, GL; Feng, YH; Huang, S; Li, GM; Li, GT; Li, J; Li, W; Li, WZ; Li, ZQ; Liang, HX; Lin, WB; Liu, N; Liu, YM; Lv, J; Pan, YJ; Song, N; Sun, CY; Wang, FS; Wang, M; Xu, GH; Xu, JH; Yu, ZJ; Zeng, QL; Zeng, YL; Zhang, DW; Zhang, GF; Zhang, GQ; Zhang, HX; Zhang, JY; Zhou, YH, 2022)
"Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent."8.12Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022)
"Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared."8.12Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022)
"To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients."7.91Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching. ( Li, T; Lin, C; Qu, Y; Wang, L; Wang, Y; Yang, B, 2019)
" She had a 7-year history of taking adefovir at 10 mg/day for chronic hepatitis B."7.88Adefovir-induced Fanconi syndrome associated with osteomalacia. ( Cha, SK; Cho, DH; Kim, HS; Kim, JH; Kim, WI; Kim, YJ; Lee, EY; Lee, JH; Lee, SM; Park, KS; Park, S, 2018)
"An increasing number of case reports suggest that acquired renal Fanconi syndrome may be associated with prolonged use of adefovir against hepatitis B virus."7.85Nephrolithiasis and Osteomalacia associated with adefovir-induced Fanconi syndrome in a patient with hepatitis B. ( Lin, J; Zhang, D; Zhuo, Y, 2017)
" This study was conducted to compare the effectiveness of lamivudine (LMV), adefovir dipivoxil (ADV), telbivudine (LdT), and entecavir (ETV) monotherapy in chronic HBeAg-negative hepatitis B patients with medium load of HBV DNA."7.85Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. ( Han, Z; Huang, M; Liu, J; Shi, H; Xia, J; Xue, J; Zhang, S; Zhu, Z, 2017)
"Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV)."7.80Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. ( Cho, M; Choi, JY; Han, KH; Hwang, JS; Kim, BI; Kim, DJ; Lee, CK; Lee, HJ; Paik, SW; Suh, DJ; Um, SH; Woo, HY; Yoon, SK, 2014)
"Adefovir (ADV) resistance is more frequent in lamivudine (LMV)-resistant chronic hepatitis B (CHB) patients than in nucleos(t)ide analogue-naïve patients."7.80Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. ( Cho, YK; Cui, XJ; Jeong, SU; Song, BC, 2014)
"In this study, a tenofovir disoproxil fumarate (TDF) + hepatitis B immunoglobulin (HBIG) regimen was compared with lamivudine (LAM) + HBIG to determine the efficacy and safety of TDF in the prevention of hepatitis B virus (HBV) recurrence following liver transplantation (LT)."7.80The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation. ( Akarsu, M; Astarcıoğlu, İ; Hakim, GD; Karademir, S; Unek, T, 2014)
"Lamivudine (LAM) has been shown to prevent de novo hepatitis B virus (HBV) infection in recipients of hepatitis B core antibody (HBcAb)-positive liver transplants (LT) but primarily in small studies with limited follow-up."7.79Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. ( Brown, RS; Brubaker, WD; Chang, MS; Emond, JC; Guarrera, JV; Olsen, SK; Pichardo, EM; Rosenthal-Cogan, L; Stiles, JB, 2013)
"This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes."7.79HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. ( Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL, 2013)
"To evaluate the effects of tenofovir disoproxil fumarate (TDF) use during late pregnancy to reduce hepatitis B virus (HBV) transmission in highly viremic mothers."7.79Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. ( Ay, M; Ayaz, C; Barcin, T; Celen, MK; Dal, MS; Dal, T; Gulsun, S; Kalkanli, S; Kaya, S; Mert, D; Yildirim, N, 2013)
"To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir."7.78Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012)
"With the increasing use of tenofovir disoproxil in the management of HIV and hepatitis B, serious adverse effects, such as renal dysfunction, will inevitably increase in frequency."7.78Severe vitamin D deficiency in a patient treated for hepatitis B with tenofovir. ( Bower, M; Kumar, N; Nelson, M, 2012)
" entecavir (ETV) monotherapy in HBeAg-positive hepatitis B patients who fail to respond to sequential treatment with LAM and ADV."7.78Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ; Son, CY, 2012)
" We report the case of a 4-month-old infant who developed fulminant hepatitis B infection and recovered concomitant with tenofovir therapy without liver transplantation."7.77Successful tenofovir treatment for fulminant hepatitis B infection in an infant. ( Alterio, A; Comparcola, D; Corsetti, T; de Ville de Goyet, J; Diamanti, A; Iacono, A; Nobili, V; Pizzichemi, G; Sartorelli, MR; Torre, G, 2011)
" His HBV is unresponsive to tenofovir/emtricitabine treatment demonstrated by persistent viremia despite lacking known resistance mutations and while having an undetectable HIV-1 viral load."7.77HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. ( Holodniy, M; Schirmer, P; Winters, M, 2011)
"Combination therapy with adefovir dipivoxil (ADV) and lamivudine (LAM) is recommended for patients infected with LAM-refractory hepatitis B virus (HBV)."7.76Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. ( Enomoto, M; Habu, D; Imanishi, Y; Iwai, S; Kawada, N; Kobayashi, S; Morikawa, H; Sakaguchi, H; Shiomi, S; Tamori, A, 2010)
"Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment-naive patients with chronic hepatitis B virus (HBV) infection but experience in nucleoside/nucleotide analogue (NA)-experienced patients is limited."7.76Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. ( Berg, T; Böcher, WO; Buggisch, P; de Man, RA; Deterding, K; Erhardt, A; Feucht, HH; Hüppe, D; Möller, B; Petersen, J; Reinders, JG; Rhode, P; Sarrazin, C; Spengler, U; Stein, K; Trojan, J; van Bömmel, F; Wasmuth, HE; Wedemeyer, H; Wiedenmann, B, 2010)
"This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV)."7.76High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B. ( Gianini, RJ; Gomes-Gouvêa, MS; Leite, OM; Locarnini, S; Martins, LG; Mendes-Correa, MC; Pinho, JR; Santana, RA; Silva, MH; Sitnik, R; Uip, DE; Yuen, L, 2010)
"To investigate the resistance mutation patterns of hepatitis B virus(HBV) during adefovir dipivoxil (ADV) monotherapy or combination therapy after lamivudine(LAM) resistance."7.76[Resistance mutation patterns of hepatitis B virus in patients with suboptimal response to adefovir dipivoxil therapy after lamivudine resistance]. ( Du, Z; Gao, YT; Hang, T; Jing, L; Li, Y; Liu, L; Liu, T; Wu, ZP, 2010)
"To establish the efficacy and safety of entecavir (ETV) and/or tenofovir (TDF) in the treatment and prevention of hepatitis B virus (HBV) recurrence after liver transplantation."7.76Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. ( de la Cruz-Lombardo, J; Jiménez-Pérez, M; Lozano-Rey, JM; Mongil Poce, L; Rodrigo-López, JM; Sáez-Gómez, AB, 2010)
"To study the efficacy and safety of entecavir (ETV) as first-line therapy for hepatitis B virus (HBV) reactivation due to immunosuppression."7.76Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. ( Brost, S; Eisenbach, C; Schnitzler, P; Stremmel, W, 2010)
"The aim of the study was to identify and characterize hepatitis B virus (HBV) polymerase gene mutations associated with ongoing HBV replication in HIV/HBV-coinfected individuals receiving tenofovir (TDF)."7.75Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. ( Arrifin, N; Audsley, J; Ayres, A; Bartholomeusz, A; Crowe, SM; Lewin, SR; Locarnini, SA; Mijch, A; Sasadeusz, J; Yuen, LK, 2009)
"Tenofovir disoproxil fumarate (TDF) is active against hepatitis B virus (HBV) and HIV."7.75Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. ( Alvarez-Uria, G; Ratcliffe, L; Vilar, J, 2009)
"Tenofovir is a new effective treatment option for patients with chronic hepatitis B, but could be potentially hampered by mutations in the hepatitis B virus (HBV) polymerase conferring drug resistance."7.75The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. ( Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Sheldon, J; Tacke, F; Trautwein, C, 2009)
"The aims of this study were to select the patients with a potential for progression to hepatic failure due to lamivudine-resistant HBV and to standardize the treatment for patients with lamivudine-resistant HBV."7.74Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. ( Hino, T; Hisamochi, A; Ide, T; Koga, H; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Sata, M; Takao, Y; Tanaka, K, 2008)
"The aim of our study was to assess the efficacy and safety of entecavir in kidney- and liver-transplant recipients with chronic hepatitis B virus (HBV) infection."7.74Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. ( Alric, L; Cointault, O; El Kahwaji, L; Izopet, J; Kamar, N; Lavayssière, L; Milioto, O; Rostaing, L; Sauné, K, 2008)
"We studied the impact of hepatitis B virus (HBV) polymerase/reverse transcriptase (Pol/Rt) heterogeneity on adefovir rescue therapy in 34 consecutive chronic hepatitis B patients with viral breakthrough during lamivudine monotherapy."7.74Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. ( Bonino, F; Brunetto, MR; Ciccorossi, P; Coco, B; Colombatto, P; Flichman, D; Maina, AM; Moriconi, F; Oliveri, F; Sacco, R, 2007)
"9-R-[2-(Phosphonomethoxy)propyl]-adenine (tenofovir) is an acyclic nucleoside phosphonate with antiviral activity against human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV)."7.74Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. ( Aldern, KA; Almond, MR; Beadle, JR; De Clercq, E; Hostetler, KY; Korba, BE; Lampert, BM; Neyts, J; Painter, GR; Trost, LC, 2007)
"The most frequently used therapy for post-transplantation recurrence of hepatitis B virus (HBV) infection is lamivudine, but this drug is associated with a high resistance rate due to YMDD mutant."7.74Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. ( Cai, CJ; Chen, GH; Jiang, H; Jiang, N; Li, H; Li, X; Lu, MQ; Wang, GS; Xu, C; Yang, Y; Yi, HM; Yi, SH; Zhang, J; Zhang, JF; Zhang, Q; Zhang, YC, 2007)
"Emergence of a lamivudine (LAM)-resistant hepatitis B virus (HBV) with amino acid substitutions in the YMDD motif is a well-documented problem during long-term LAM therapy."7.74Successful treatment of an entecavir-resistant hepatitis B virus variant. ( Abe, H; Chayama, K; Fujimoto, Y; Hatakeyama, T; Hiraga, N; Imamura, M; Kumada, H; Maekawa, T; Mori, N; Ochi, H; Suzuki, F; Takahashi, S; Tsuge, M; Yatsuji, H, 2007)
"Treatment of post-transplantation recurrence of hepatitis B virus (HBV) infection despite prophylaxis with hepatitis B immunoglobulin (HBIG) and lamivudine combination therapy is not easy."7.74Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. ( Akyildiz, M; Aydin, U; Karasu, Z; Kilic, M; Ozacar, T; Zeytunlu, M, 2007)
"The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis B virus (HBV) infection and clinical or virologic resistance to LAM."7.74Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. ( Armignacco, O; Barbarini, G; Barbaro, G; Barlattani, A; Camporiondo, MP; Ferri, F; Francavilla, R; Mazzoni, E; Mecenate, F; Nauri, L; Nosotti, L; Paffetti, A; Pellicelli, AM; Romano, M; Soccorsi, F; Struglia, C; Villani, R, 2008)
"Lamivudine is a safe, effective treatment for hepatitis B virus (HBV) reactivation after renal transplantation."7.73Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. ( Ceballos, M; Diaz, F; Garcia, A; Garcia, T; González, P; Mazuecos, A; Rivero, M, 2005)
"Antiviral treatment can be complex in decompensated hepatitis B virus (HBV) cirrhosis because of potential emergence of lamivudine-resistant mutants and worsening liver function, and to multifactorial nephrotoxicity."7.73Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. ( Cañas, C; Casais, LA; Casanova, A; Chahri, N; Figueras, J; Gornals, J; Lopez, C; Taltavull, TC; Verdura, B, 2005)
"Adefovir dipivoxil is effective in patients with lamivudine-resistant hepatitis B virus (HBV)."7.73[Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease]. ( Choi, MS; Koh, KC; Lee, JH; Moon, W; Moon, YM; Paik, SW; Rhee, JC; Shim, SG; Yoo, BC, 2005)
"The susceptibility of adefovir-resistant hepatitis B virus (HBV) mutants is only reduced by 3-10-fold in in vitro studies, suggesting that virologic breakthrough and clinical deterioration are unlikely."7.73Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. ( Andreone, P; Cursaro, C; Fung, SK; Han, SH; Hussain, M; Keeffe, EB; Lok, AS; Marrero, JA; Rajender Reddy, K; Regev, A; Richtmyer, P, 2005)
"Progression of hepatitis B in patients with lamivudine-resistant strains is slowed down by adefovir dipivoxil (ADV)."7.73Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. ( Colombo, M; Iavarone, M; Lampertico, P; Lunghi, G; Manenti, E; Viganò, M, 2005)
"Tenofovir disoproxil fumarate (TDF) has shown in vitro activity against both HIV and hepatitis B virus (HBV)."7.73Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. ( Benhamou, Y; Fleury, H; Katlama, C; Le Teuff, G; Pellegrin, I; Piketty, C; Rozenbaum, W; Trimoulet, P; Trylesinski, A; Urbinelli, R, 2006)
"Incomplete virological response to adefovir dipivoxil (ADV) has been observed in patients with lamivudine-resistant hepatitis B virus (HBV) infection and may be associated with developing resistance and disease progression."7.73Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. ( Berg, T; Feucht, HH; Hüppe, D; Möller, B; Sarrazin, C; Spengler, U; van Bömmel, F; Wiedenmann, B; Zöllner, B, 2006)
"We report the treatment outcome in six post-renal transplant patients with lamivudine-resistant hepatitis B virus (LR-HBV) infection using adefovir dipivoxil and followed for 6 to 18 months."7.73Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. ( Dassanayake, AS; de Silva, AP; de Silva, HJ; Manamperi, A, 2006)
"We report a patient whose cryoglobulinemic vasculitis recurred due to reactivation of lamivudine-resistant HBV."7.73Successful treatment with adefovir of one patient whose cryoglobulinemic vasculitis relapsed under lamivudine therapy and who was diagnosed to have HBV virologic breakthrough with YMDD mutations. ( Cakir, N; Midilli, K; Pamuk, ON; Umit, H, 2006)
" A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis."7.72Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003)
"Emergence of lamivudine-resistant hepatitis B virus (HBV) is a major concern in human immunodeficiency virus (HIV) and HBV coinfected patients."7.72In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. ( Benhamou, Y; Cahour, A; Katlama, C; Lada, O; Poynard, T; Thibault, V, 2004)
"ADV is an effective rescue therapy for patients with lamivudine-resistant hepatitis B post-liver transplant."7.72Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. ( Da Costa, M; Dan, YY; Isaac, J; Lee, HL; Lee, KH; Lee, YM; Lim, SG; Mak, K; Prabhakaran, K; Sutedja, DS; Wai, CT; Wee, A, 2004)
"Adefovir dipivoxil (ADV) is a nucleoside analogue that inhibits wild-type hepatitis B virus (HBV) and lamivudine-resistant HBV mutants in vitro and in vivo."7.72Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. ( Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2004)
"Three HIV-infected patients with chronic hepatitis B (genotype A) were switched to adefovir therapy after unsuccessful lamivudine treatment."7.72Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. ( Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L, 2004)
"Failure of prophylaxis for hepatitis B virus (HBV) recurrence in liver transplant patients with HBV immunoglobulin (HBIG) or lamivudine or both can be associated with rapid development of liver failure."7.72Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin. ( Akay, S; Akyildiz, M; Karasu, Z; Tokat, Y, 2004)
"Lamivudine-resistant hepatitis B virus (HBV) is found in about 15-32% of infected patients with or without co-infection with HIV-1 after 1 year of lamivudine therapy."7.71Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. ( Benhamou, Y; Bochet, M; Brosgart, C; Calvez, V; Fievet, MH; Fry, J; Gibbs, CS; Katlama, C; Namini, H; Poynard, T; Thibault, V; Vig, P, 2001)
"Oral adefovir dipivoxil (ADV) reduced viral load in transgenic mice expressing hepatitis B virus (HBV)."7.71Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. ( Julander, JG; Morrey, JD; Sidwell, RW, 2002)
" Hepatitis B immunoglobulin and adefovir dipivoxil were initiated."7.70Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. ( Gibbs, CS; Howard, T; Jacobsmeyer, S; Lamy, P; Murray, A; Peters, MG; Singer, G; Xiong, X, 1999)
"Our aim is to selectively deliver 9-(2-phosphonylmethoxyethyl)adenine (PMEA) to parenchymal liver cells, the primary site of hepatitis B virus (HBV) infection."7.70Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B. ( Balzarini, J; Biessen, EA; Bijsterbosch, MK; de Vrueh, RL; Rump, ET; van Berkel, TJ; van De Bilt, E; van Veghel, R, 2000)
"Among 3656 highly viremic mothers treated with TDF, hepatitis B virus DNA suppression to the levels <200,000 IU/mL at delivery was achieved in 34% to 100% of mothers."7.01The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B. ( Deng, Y; Pan, CQ; Park, J; Zhu, L, 2023)
" However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months."7.01Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. ( Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023)
" In conclusion, a combination of LAM and ADV initiated at the time of wait listing provides safe and effective protection against recurrent HBV infection without the high costs and inconvenience associated with long-term HBIG therapy."6.78Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. ( Angus, PW; Gane, EJ; McCaughan, GW; Patterson, S; Strasser, SI, 2013)
"Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern."6.77Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. ( Bozkaya, H; Cakaloglu, Y; Chatzikyrkou, C; Dalekos, GN; Erhardt, A; Großhennig, A; Gurel, S; Manns, MP; Mederacke, I; Wedemeyer, H; Yalcin, K; Yurdaydin, C; Zachou, K; Zeuzem, S, 2012)
"Adefovir resistance was detected in two patients."6.76Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. ( Deutsch, M; Ketikoglou, I; Manesis, EK; Manolakopoulos, S; Mela, M; Papatheodoridis, GV; Striki, A; Tzourmakliotis, D, 2011)
"Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus-1 (HIV-1) and hepatitis C virus."6.74Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. ( Avihingsanon, A; Bowden, S; Dore, GJ; Lewin, SR; Locarnini, SA; Marks, P; Matthews, G; Perelson, AS; Ribeiro, RM; Ruxrungtham, K, 2009)
"Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients."6.73Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. ( Benhamou, Y; Dominguez, S; Duvivier, C; Ingiliz, P; Katlama, C; Poynard, T; Thibault, V; Valantin, MA, 2008)
" Adefovir dipivoxil (ADV) liquid suspension (GS-02-526), as a new form of oral ADV, not only has competent antiviral efficacy, but is also more convenient for patients with swallowing difficulties or patients with impaired renal function requiring dosage adjustment."6.50Liquid oral suspension adefovir dipivoxil (GS-02-526): an update on treatments for hepatitis B infection. ( Chen, EQ; Shi, Y; Tang, H; Wu, DB, 2014)
"Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV."5.48Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018)
"The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients."5.41Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023)
"Tenofovir disoproxil fumarate (TDF) is a novel nucleotide reverse transcriptase inhibitor that is mainly used to treat human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections."5.41[Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile]. ( Duan, YQ; Hu, P, 2023)
"Adefovir dipivoxil (AD) is a nucleotide analogue of adenosine that has achieved significant results in virologic, biochemical, and clinical parameters in lamivudine-resistant HBV-infected patients."5.33Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. ( Barrios Peinado, C; Cuervas-Mons Martínez, V; Herreros de Tejada Echanojáuregui, A; López Monclús, J; Lucena de la Poza, JL; Moreno Planas, JM; Portero Azorin, F; Revilla Negro, J; Rubio González, E; Sánchez Turrión, V, 2005)
"Treatment with lamivudine is initially efficient in both infections but the incidence of lamivudine-resistant HBV emergence increases over time."5.33Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. ( Avilés, JF; Bárcena, R; Barrios, C; Buti, M; Casanovas, T; Cuervas, V; De la Mata, M; Del Campo, S; Delgado, M; Dieguez, ML; Fraga, E; Gonzalez, A; Herrero, JI; Loinaz, C; Mas, A; Moraleda, G; Moreno, JM; Muñoz, R; Otero, A; Prieto, M; Rueda, M; Sousa, JM, 2005)
"Adefovir was administered for six consecutive days starting one day before or four days after DHBV inoculation."5.31Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. ( Delmas, J; Gibbs, C; Hantz, O; Jamard, C; Schorr, O; Trépo, C; Zoulim, F, 2002)
"Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes."5.2796 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. ( Agarwal, K; Ahn, SH; Bae, H; Bhardwaj, N; Brunetto, M; Buti, M; Cathcart, AL; Çelen, MK; Chan, HLY; Chuang, WL; Flaherty, JF; Fung, S; Furusyo, N; Gaggar, A; Gane, EJ; Izumi, N; Janssen, HLA; Lau, AH; Lim, YS; Lin, L; Mani Subramanian, G; Marcellin, P; Pan, CQ; Seto, WK; Shalimar, D; Sharma, M; Suri, V; Trinh, H; Yoon, KT, 2018)
"Adefovir, a nucleotide analog developed by John Martin, was a major breakthrough in the treatment of chronic Hepatitis B."5.22Adefovir for lamivudine-resistant hepatitis B. ( Dieterich, D; Roediger, R; Smyth, EK, 2022)
"Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B."5.22Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016)
"In patients with hepatitis B-related HCC, adefovir antiviral therapy reduced late HCC recurrence and significantly improved overall survival after R0 hepatic resection."5.20Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. ( Huang, G; Lau, WY; Pan, ZY; Shen, F; Wang, ZG; Wu, MC; Yuan, SX; Zhou, WP, 2015)
"We examined the durability of the virological response after discontinuing lamivudine (LVD) in chronic hepatitis B (CHB) patients with LVD-resistant hepatitis B virus (HBV), who responded to LVD plus adefovir (ADV) combination therapy, and the outcome of switching to ADV monotherapy compared to maintaining combination therapy."5.19Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, HS; Kim, MN; Kim, SU; Lee, CK; Lee, S; Park, JY, 2014)
"To investigate the efficacy and safety of combined de novo lamivudine (LAM) and adefovir dipivoxil (ADV) therapy in hepatitis B virus (HBV)-related decompensated liver cirrhosis patients."5.17Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. ( Chen, Y; Li, LJ; Lv, GC; Sheng, JF; Yang, YD; Yao, JM; Zheng, L, 2013)
" Tenofovir dipivoxil, a novel ester prodrug of tenofovir, can be used for treatment for hepatitis B and HIV infection and it was necessary to evaluate the effect of its treatment on carnitine homeostasis."5.17Impact on L-carnitine Homeostasis of Short-term Treatment with the Pivalate Prodrug Tenofovir Dipivoxil. ( Feng, J; Hang, TJ; Jia, YY; Lu, CT; Song, Y; Sun, Y; Wang, S; Wen, AD; Yang, ZF; Zhao, JY, 2013)
"To compare efficacy of combined lamivudine (LAM) and adefovir dipivoxil (ADV) therapy with that of entecavir (ETV) monotherapy for hepatitis B virus (HBV)-related decompensated liver cirrhosis."5.17De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. ( Chen, JY; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2013)
" At month 24, virological response rate [hepatitis B virus (HBV) DNA <60 IU/ml] was higher in the adefovir-lamivudine combination group compared with entecavir group (56."5.17Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Um, SH; Yim, HJ; Yoon, EL, 2013)
"Adefovir dipivoxil has activity against wild-type and lamivudine-resistant hepatitis B virus (HBV) and is frequently used to manage HBV infection in transplant recipients."5.14Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. ( Brown, RS; Enejosa, J; McGuire, BM; Ramanathan, S; Schiff, E; Terrault, NA; Tran, TT; Tupper, R; Zhong, L; Zong, J, 2009)
"Adefovir dipivoxil (ADV) is effective in lamivudine (LAM)-resistant hepatitis B e antigen-negative (HBeAg(-)) chronic hepatitis B (CHB)."5.14Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. ( Eugenidis, N; Giouleme, O; Gkisakis, D; Grammatikos, N; Katsinelos, P; Koumaras, H; Koumerkeridis, G; Mpoumponaris, A; Panderi, A; Patsiaoura, K; Theodoropoulos, K; Tziomalos, K; Vassiliadis, TG, 2010)
"To investigate the efficacy and safety of adefovir dipivoxil (ADV) in treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis."5.13[Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis]. ( Chen, YS; Jin, ZJ; Li, DF; Qiao, LM; Zhou, J, 2008)
"The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations."5.13Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. ( Calabresi, A; Carosi, G; Cologni, G; Costarelli, S; Lapadula, G; Puoti, M; Quiros-Roldan, E; Tirelli, V; Torti, C; Zaltron, S, 2008)
"We previously reported that 48 weeks of combination therapy with pegylated interferon-alpha2b (PEG-IFN-alpha2b) and adefovir dipivoxil (ADV) in patients with chronic hepatitis B led to marked decreases of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) (-2."5.13Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. ( Dandri, M; Fischer, C; Lutgehetmann, M; Petersen, J; Quaas, A; Volzt, T; Zankel, M, 2008)
"The addition of adefovir dipivoxil (ADV) to ongoing lamivudine therapy is effective against lamivudine-resistant virus in patients with hepatitis B virus (HBV) infection."5.12Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. ( Kumada, H; Nakamura, H; Suzuki, F, 2006)
"Adefovir dipivoxil (ADV) is a nucleotide analogue that is known to be effective for lamivudine-resistant hepatitis B virus (HBV) mutants as well as wild-type HBV."5.12Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. ( Cho, YS; Kim, DH; Kim, DY; Kim, HJ; Lee, CK; Park, BK; Park, IS; Suh, JH; Won, SY, 2007)
"Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively."5.12Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. ( Arterburn, S; Borroto-Esoda, K; Brosgart, C; Chuck, S; Colombo, M; Hadziyannis, S; Lai, CL; Neuhaus, P; Samuel, D; Schiff, E; Terrault, N; Tillmann, H; Villeneuve, JP; Zeuzem, S, 2007)
"Low-dose TDF monotherapy can control HBV viremia for an extended period of time without the emergence of resistance and is more potent than adefovir at the standard dosage."5.12Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. ( Colombo, S; Del Poggio, P; Jamoletti, C; Oggionni, M; Puhalo, V; Zaccanelli, M, 2007)
"Adefovir monotherapy is an established treatment modality for lamivudine-experienced patients with chronic hepatitis B, but it carries a significant risk of resistance in the long term."5.12Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. ( Colombo, M; Iavarone, M; Lampertico, P; Manenti, E; Sablon, E; Viganò, M, 2007)
"Phase II and III clinical trials of adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B have shown that this hepadnavirus polymerase inhibitor is well tolerated and effectively suppresses hepatitis B virus (HBV) replication."5.11Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. ( Cinquin, K; Marcellin, P; Maynard, M; Pol, S; Trépo, C; Werle, B; Zoulim, F, 2004)
"We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir."5.11Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. ( Bani-Sadr, F; Molina, JM; Palmer, P; Scieux, C, 2004)
"The purpose of this prospective study was to evaluate the efficacy and safety of adefovir dipivoxil with or without ongoing lamivudine in decompensated lamivudine-resistant chronic hepatitis B patients."5.11Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. ( Choi, WB; Chung, YH; Kim, KM; Lee, HC; Lee, YS; Lim, YS; Suh, DJ, 2005)
"Tenofovir (TFV) is the cornerstone of the treatment and prophylaxis of HIV infections."4.98Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. ( De Clercq, E, 2018)
"The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations."4.98Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. ( Asriel, B; Chan, L; Eaton, EF; Wyatt, CM, 2018)
"Lamivudine and tenofovir disoproxil fumarate (TDF) are both active against hepatitis B virus (HBV)."4.91Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. ( Ehrhardt, S; Guo, N; Nelson, K; Thio, CL; Xie, C, 2015)
"Antiviral therapy using newer nucleos(t)ide analogues with lower resistance rates such as entecavir or tenofovir could suppress hepatitis B virus (HBV) replication, improve liver function, delay or obviate the need for liver transplantation in some patients, and reduce the risk of HBV recurrence."4.90Prevention of hepatitis B virus reinfection in liver transplant recipients. ( Roche, B; Samuel, D, 2014)
"The use of the acyclic nucleoside phosphonates, starting with (S)-HPMPA as the prototype, yielded three clinically approved antiviral drugs, cidofovir for the treatment of CMV retinitis in AIDS patients, adefovir dipivoxil for the treatment of chronic hepatitis B and tenofovir disoproxil fumarate for the treatment of HIV infections (AIDS) and HBV infections."4.87The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond. ( De Clercq, E, 2011)
"Randomised clinical trials addressing benefits and harms of lamivudine or adefovir dipivoxil alone or in combination with hepatitis B immunoglobulins (HBIg) for preventing recurrent HBV infection in patients who are liver transplanted due to HBV infection with or without hepatocellular carcinoma."4.86Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. ( Guy, DG; Katz, LH; Paul, M; Tur-Kaspa, R, 2010)
"The established gold standard for prophylaxis against hepatitis B virus (HBV) recurrence post-liver transplant is combination hepatitis B immune globulin (HBIG) and lamivudine."4.85Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. ( Angus, PW; Patterson, SJ, 2009)
" In the last few years the therapeutic options in chronic hepatitis B have increased and currently six treatments are authorized: standard interferon (IFN)-alpha, pegylated interferon-alpha (PEG-IFNalpha), lamivudine, adefovir, entecavir, and telbivudine."4.84[Interferon in hepatitis B]. ( García Buey, L; González Mateos, F; Moreno Otero, R, 2008)
" Chronic hepatitis C can be treated preferably with a combination therapy (pegylated interferons + Ribavirin)."4.82[Hepatitis: associated diseases. Risk groups -- prevention -- treatment]. ( Maier, KP, 2003)
"In this article, we review modeling and interpretation of kinetics data obtained from patients with chronic hepatitis B virus infection that has been treated with lamivudine, adefovir dipivoxil, and lamivudine plus famciclovir combination therapy."4.82Hepatitis B virus kinetics and mathematical modeling. ( Perelson, AS; Ribeiro, RM, 2004)
"Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects."4.12Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide ( Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML, 2022)
"Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking."4.12Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. ( Chen, ZM; Cui, GL; Feng, YH; Huang, S; Li, GM; Li, GT; Li, J; Li, W; Li, WZ; Li, ZQ; Liang, HX; Lin, WB; Liu, N; Liu, YM; Lv, J; Pan, YJ; Song, N; Sun, CY; Wang, FS; Wang, M; Xu, GH; Xu, JH; Yu, ZJ; Zeng, QL; Zeng, YL; Zhang, DW; Zhang, GF; Zhang, GQ; Zhang, HX; Zhang, JY; Zhou, YH, 2022)
"Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent."4.12Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022)
"Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared."4.12Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022)
"To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients."3.91Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching. ( Li, T; Lin, C; Qu, Y; Wang, L; Wang, Y; Yang, B, 2019)
"Adefovir dipivoxil is a nucleotide analogue that is approved for treatment of chronic hepatitis B."3.91Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report. ( Aso, Y; Iijima, T; Jojima, T; Kase, M; Kogai, T; Kunii, T; Sakurai, S; Shimizu, M; Usui, I, 2019)
"The present study aimed to prepare proliposomal formulae for improving the oral bioavailability of adefovir dipivoxil (AD), a nucleoside reverse transcriptase inhibitor effective against hepatitis B virus (HBV)."3.88Adefovir dipivoxil loaded proliposomal powders with improved hepatoprotective activity: formulation, optimization, pharmacokinetic, and biodistribution studies. ( Abdelbary, GA; Amin, MM; El Awdan, SA; Zakaria, MY, 2018)
" She had a 7-year history of taking adefovir at 10 mg/day for chronic hepatitis B."3.88Adefovir-induced Fanconi syndrome associated with osteomalacia. ( Cha, SK; Cho, DH; Kim, HS; Kim, JH; Kim, WI; Kim, YJ; Lee, EY; Lee, JH; Lee, SM; Park, KS; Park, S, 2018)
"An increasing number of case reports suggest that acquired renal Fanconi syndrome may be associated with prolonged use of adefovir against hepatitis B virus."3.85Nephrolithiasis and Osteomalacia associated with adefovir-induced Fanconi syndrome in a patient with hepatitis B. ( Lin, J; Zhang, D; Zhuo, Y, 2017)
" This study was conducted to compare the effectiveness of lamivudine (LMV), adefovir dipivoxil (ADV), telbivudine (LdT), and entecavir (ETV) monotherapy in chronic HBeAg-negative hepatitis B patients with medium load of HBV DNA."3.85Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. ( Han, Z; Huang, M; Liu, J; Shi, H; Xia, J; Xue, J; Zhang, S; Zhu, Z, 2017)
"Low-dose hepatitis B immunoglobulin (HBIG) and nucleos(t)ides analogs (lamivudine/adefovir) used for the prevention of hepatitis B virus (HBV) recurrence after liver transplantation (LT) are associated with some risk of HBV recurrence and antiviral resistance."3.81Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis? ( Choudhary, NS; Goja, S; Menon, PB; Mohanka, R; Rastogi, A; Saigal, S; Saraf, N; Soin, AS, 2015)
"Adefovir dipivoxil (ADV) is used as first-line monotherapy or rescue therapy in chronic hepatitis B (CHB) patients."3.81A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response. ( Chen, J; Deng, H; Guo, JJ; Huang, A; Huang, WX; Huang, Y; Shan, X; Shan, YL; Tang, N; Wang, YW; Zhang, DZ, 2015)
"The present report describes a case of a patient with hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infection who was treated with tenofovir disoproxil (TDF)-based highly active antiretroviral therapy (HAART) and who achieved HBs antigen (Ag)/antibody (Ab) seroconversion."3.80An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion. ( Abe, M; Hiasa, Y; Hirooka, M; Ikeda, Y; Koizumi, Y; Kumagi, T; Matsuura, B; Ochi, H; Tada, F; Takada, K; Tokumoto, Y; Watanabe, T, 2014)
"Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV)."3.80Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. ( Cho, M; Choi, JY; Han, KH; Hwang, JS; Kim, BI; Kim, DJ; Lee, CK; Lee, HJ; Paik, SW; Suh, DJ; Um, SH; Woo, HY; Yoon, SK, 2014)
"Adefovir (ADV) resistance is more frequent in lamivudine (LMV)-resistant chronic hepatitis B (CHB) patients than in nucleos(t)ide analogue-naïve patients."3.80Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. ( Cho, YK; Cui, XJ; Jeong, SU; Song, BC, 2014)
" Three of the 12 patients who were treated with combination therapy group were carriers of YMDD mutants and all three showed improvement in liver function and hepatic histology after receiving adefovir dipivoxil,instead of lamivudine,in the early stage of recurrent hepatitis B after OLT."3.80[Clinical pathology of recurrent hepatitis B after liver transplantation]. ( Jiao, Z; Yan, L; Zhang, D, 2014)
"In this study, a tenofovir disoproxil fumarate (TDF) + hepatitis B immunoglobulin (HBIG) regimen was compared with lamivudine (LAM) + HBIG to determine the efficacy and safety of TDF in the prevention of hepatitis B virus (HBV) recurrence following liver transplantation (LT)."3.80The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation. ( Akarsu, M; Astarcıoğlu, İ; Hakim, GD; Karademir, S; Unek, T, 2014)
"Lamivudine (LAM) has been shown to prevent de novo hepatitis B virus (HBV) infection in recipients of hepatitis B core antibody (HBcAb)-positive liver transplants (LT) but primarily in small studies with limited follow-up."3.79Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. ( Brown, RS; Brubaker, WD; Chang, MS; Emond, JC; Guarrera, JV; Olsen, SK; Pichardo, EM; Rosenthal-Cogan, L; Stiles, JB, 2013)
"This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes."3.79HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. ( Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL, 2013)
"To evaluate the effects of tenofovir disoproxil fumarate (TDF) use during late pregnancy to reduce hepatitis B virus (HBV) transmission in highly viremic mothers."3.79Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. ( Ay, M; Ayaz, C; Barcin, T; Celen, MK; Dal, MS; Dal, T; Gulsun, S; Kalkanli, S; Kaya, S; Mert, D; Yildirim, N, 2013)
"To investigate the molecular mechanisms underlying the influence of DNA polymerase from different genotypes of hepatitis B virus (HBV) on the binding affinity of adefovir (ADV)."3.79Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies. ( Du, Y; Huang, AL; Jiang, HL; Li, J; Liu, X; Luo, XM; Shen, QC; Zheng, MY, 2013)
"To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir."3.78Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012)
"With the increasing use of tenofovir disoproxil in the management of HIV and hepatitis B, serious adverse effects, such as renal dysfunction, will inevitably increase in frequency."3.78Severe vitamin D deficiency in a patient treated for hepatitis B with tenofovir. ( Bower, M; Kumar, N; Nelson, M, 2012)
" Treatment naive chronic hepatitis C patients should initially receive pegylated interferon and ribavirin dual combination therapy."3.78[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis]. ( Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I; Ujhelyi, E, 2012)
" entecavir (ETV) monotherapy in HBeAg-positive hepatitis B patients who fail to respond to sequential treatment with LAM and ADV."3.78Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ; Son, CY, 2012)
" Genotype has been compared with treatment response in children infected perinatally with hepatitis B following treatment with oral antiviral drugs (lamivudine or adefovir) or interferon (IFN) alone and with prednisolone priming (Pred/IFN)."3.78Does genotype predict response to treatment in children infected with hepatitis B perinatally? ( Boxall, E; Kaskar, S; Kelly, D; Sira, J; Workman, J, 2012)
"Data on the efficacy of lamivudine (LAM)-, tenofovir (TDF)- and emtricitabine (FTC)-based antiretroviral therapy (HAART) in HBV-HIV coinfection are limited."3.78Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. ( Grabmeier-Pfistershammer, K; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R, 2012)
" We report the case of a 4-month-old infant who developed fulminant hepatitis B infection and recovered concomitant with tenofovir therapy without liver transplantation."3.77Successful tenofovir treatment for fulminant hepatitis B infection in an infant. ( Alterio, A; Comparcola, D; Corsetti, T; de Ville de Goyet, J; Diamanti, A; Iacono, A; Nobili, V; Pizzichemi, G; Sartorelli, MR; Torre, G, 2011)
" His HBV is unresponsive to tenofovir/emtricitabine treatment demonstrated by persistent viremia despite lacking known resistance mutations and while having an undetectable HIV-1 viral load."3.77HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. ( Holodniy, M; Schirmer, P; Winters, M, 2011)
"Combination therapy with adefovir dipivoxil (ADV) and lamivudine (LAM) is recommended for patients infected with LAM-refractory hepatitis B virus (HBV)."3.76Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. ( Enomoto, M; Habu, D; Imanishi, Y; Iwai, S; Kawada, N; Kobayashi, S; Morikawa, H; Sakaguchi, H; Shiomi, S; Tamori, A, 2010)
"Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment-naive patients with chronic hepatitis B virus (HBV) infection but experience in nucleoside/nucleotide analogue (NA)-experienced patients is limited."3.76Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. ( Berg, T; Böcher, WO; Buggisch, P; de Man, RA; Deterding, K; Erhardt, A; Feucht, HH; Hüppe, D; Möller, B; Petersen, J; Reinders, JG; Rhode, P; Sarrazin, C; Spengler, U; Stein, K; Trojan, J; van Bömmel, F; Wasmuth, HE; Wedemeyer, H; Wiedenmann, B, 2010)
"Pre-existing antiviral-resistant hepatitis B virus (HBV) has been associated with primary non-response to lamivudine treatment in patients with chronic hepatitis B, but little is known of the capacity for resistant HBV to cause primary infection."3.76Acute hepatitis B infection associated with drug-resistant hepatitis B virus. ( Chen, L; Liu, Y; Ren, X; Si, L; Wang, Y; Xu, D; Xu, T; Xu, Z; Zhao, J; Zhong, Y, 2010)
"This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV)."3.76High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B. ( Gianini, RJ; Gomes-Gouvêa, MS; Leite, OM; Locarnini, S; Martins, LG; Mendes-Correa, MC; Pinho, JR; Santana, RA; Silva, MH; Sitnik, R; Uip, DE; Yuen, L, 2010)
"To investigate the resistance mutation patterns of hepatitis B virus(HBV) during adefovir dipivoxil (ADV) monotherapy or combination therapy after lamivudine(LAM) resistance."3.76[Resistance mutation patterns of hepatitis B virus in patients with suboptimal response to adefovir dipivoxil therapy after lamivudine resistance]. ( Du, Z; Gao, YT; Hang, T; Jing, L; Li, Y; Liu, L; Liu, T; Wu, ZP, 2010)
"To establish the efficacy and safety of entecavir (ETV) and/or tenofovir (TDF) in the treatment and prevention of hepatitis B virus (HBV) recurrence after liver transplantation."3.76Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. ( de la Cruz-Lombardo, J; Jiménez-Pérez, M; Lozano-Rey, JM; Mongil Poce, L; Rodrigo-López, JM; Sáez-Gómez, AB, 2010)
"To study the efficacy and safety of entecavir (ETV) as first-line therapy for hepatitis B virus (HBV) reactivation due to immunosuppression."3.76Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. ( Brost, S; Eisenbach, C; Schnitzler, P; Stremmel, W, 2010)
"The aim of the study was to identify and characterize hepatitis B virus (HBV) polymerase gene mutations associated with ongoing HBV replication in HIV/HBV-coinfected individuals receiving tenofovir (TDF)."3.75Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. ( Arrifin, N; Audsley, J; Ayres, A; Bartholomeusz, A; Crowe, SM; Lewin, SR; Locarnini, SA; Mijch, A; Sasadeusz, J; Yuen, LK, 2009)
"Tenofovir disoproxil fumarate (TDF) is active against hepatitis B virus (HBV) and HIV."3.75Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. ( Alvarez-Uria, G; Ratcliffe, L; Vilar, J, 2009)
"Tenofovir is a new effective treatment option for patients with chronic hepatitis B, but could be potentially hampered by mutations in the hepatitis B virus (HBV) polymerase conferring drug resistance."3.75The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. ( Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Sheldon, J; Tacke, F; Trautwein, C, 2009)
"Adefovir dipivoxil (ADV) is effective for treatment of chronic hepatitis B virus (HBV) infection, but long-time ADV therapy leads to drug resistance because of HBV reverse transcriptase mutations."3.75Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay. ( Chen, M; Pu, XK; Ruan, LH; Shen, HY; Wang, YZ; Wu, GX; Xiao, JH; Zhang, HY, 2009)
"The aims of this study were to select the patients with a potential for progression to hepatic failure due to lamivudine-resistant HBV and to standardize the treatment for patients with lamivudine-resistant HBV."3.74Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. ( Hino, T; Hisamochi, A; Ide, T; Koga, H; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Sata, M; Takao, Y; Tanaka, K, 2008)
"The aim of our study was to assess the efficacy and safety of entecavir in kidney- and liver-transplant recipients with chronic hepatitis B virus (HBV) infection."3.74Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. ( Alric, L; Cointault, O; El Kahwaji, L; Izopet, J; Kamar, N; Lavayssière, L; Milioto, O; Rostaing, L; Sauné, K, 2008)
"We studied the impact of hepatitis B virus (HBV) polymerase/reverse transcriptase (Pol/Rt) heterogeneity on adefovir rescue therapy in 34 consecutive chronic hepatitis B patients with viral breakthrough during lamivudine monotherapy."3.74Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. ( Bonino, F; Brunetto, MR; Ciccorossi, P; Coco, B; Colombatto, P; Flichman, D; Maina, AM; Moriconi, F; Oliveri, F; Sacco, R, 2007)
"Adefovir dipivoxil is a nucleotide prodrug approved for the treatment of chronic hepatitis B."3.74In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. ( Delaney, WE; Miller, M; Qi, X; Xiong, S; Yang, H, 2007)
"9-R-[2-(Phosphonomethoxy)propyl]-adenine (tenofovir) is an acyclic nucleoside phosphonate with antiviral activity against human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV)."3.74Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. ( Aldern, KA; Almond, MR; Beadle, JR; De Clercq, E; Hostetler, KY; Korba, BE; Lampert, BM; Neyts, J; Painter, GR; Trost, LC, 2007)
"The most frequently used therapy for post-transplantation recurrence of hepatitis B virus (HBV) infection is lamivudine, but this drug is associated with a high resistance rate due to YMDD mutant."3.74Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. ( Cai, CJ; Chen, GH; Jiang, H; Jiang, N; Li, H; Li, X; Lu, MQ; Wang, GS; Xu, C; Yang, Y; Yi, HM; Yi, SH; Zhang, J; Zhang, JF; Zhang, Q; Zhang, YC, 2007)
"Emergence of a lamivudine (LAM)-resistant hepatitis B virus (HBV) with amino acid substitutions in the YMDD motif is a well-documented problem during long-term LAM therapy."3.74Successful treatment of an entecavir-resistant hepatitis B virus variant. ( Abe, H; Chayama, K; Fujimoto, Y; Hatakeyama, T; Hiraga, N; Imamura, M; Kumada, H; Maekawa, T; Mori, N; Ochi, H; Suzuki, F; Takahashi, S; Tsuge, M; Yatsuji, H, 2007)
"Treatment of post-transplantation recurrence of hepatitis B virus (HBV) infection despite prophylaxis with hepatitis B immunoglobulin (HBIG) and lamivudine combination therapy is not easy."3.74Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. ( Akyildiz, M; Aydin, U; Karasu, Z; Kilic, M; Ozacar, T; Zeytunlu, M, 2007)
"The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis B virus (HBV) infection and clinical or virologic resistance to LAM."3.74Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. ( Armignacco, O; Barbarini, G; Barbaro, G; Barlattani, A; Camporiondo, MP; Ferri, F; Francavilla, R; Mazzoni, E; Mecenate, F; Nauri, L; Nosotti, L; Paffetti, A; Pellicelli, AM; Romano, M; Soccorsi, F; Struglia, C; Villani, R, 2008)
"The efficiacy of Entecavir and Adefovir for treatment of acute hepatitis B is not known."3.74[Acute hepatitis B: is antiviral therapy indicated? Two case reports]. ( Girke, J; Manns, MP; Tillmann, HL; Wedemeyer, H; Wiegand, J, 2008)
"Lamivudine is a safe, effective treatment for hepatitis B virus (HBV) reactivation after renal transplantation."3.73Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. ( Ceballos, M; Diaz, F; Garcia, A; Garcia, T; González, P; Mazuecos, A; Rivero, M, 2005)
"Antiviral treatment can be complex in decompensated hepatitis B virus (HBV) cirrhosis because of potential emergence of lamivudine-resistant mutants and worsening liver function, and to multifactorial nephrotoxicity."3.73Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. ( Cañas, C; Casais, LA; Casanova, A; Chahri, N; Figueras, J; Gornals, J; Lopez, C; Taltavull, TC; Verdura, B, 2005)
"Adefovir dipivoxil is effective in patients with lamivudine-resistant hepatitis B virus (HBV)."3.73[Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease]. ( Choi, MS; Koh, KC; Lee, JH; Moon, W; Moon, YM; Paik, SW; Rhee, JC; Shim, SG; Yoo, BC, 2005)
"The susceptibility of adefovir-resistant hepatitis B virus (HBV) mutants is only reduced by 3-10-fold in in vitro studies, suggesting that virologic breakthrough and clinical deterioration are unlikely."3.73Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. ( Andreone, P; Cursaro, C; Fung, SK; Han, SH; Hussain, M; Keeffe, EB; Lok, AS; Marrero, JA; Rajender Reddy, K; Regev, A; Richtmyer, P, 2005)
"Progression of hepatitis B in patients with lamivudine-resistant strains is slowed down by adefovir dipivoxil (ADV)."3.73Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. ( Colombo, M; Iavarone, M; Lampertico, P; Lunghi, G; Manenti, E; Viganò, M, 2005)
"Tenofovir disoproxil fumarate (TDF) has shown in vitro activity against both HIV and hepatitis B virus (HBV)."3.73Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. ( Benhamou, Y; Fleury, H; Katlama, C; Le Teuff, G; Pellegrin, I; Piketty, C; Rozenbaum, W; Trimoulet, P; Trylesinski, A; Urbinelli, R, 2006)
"Hepatitis B immunoglobulin with lamivudine prophylaxis (LAM/HBIG) is effective in preventing Hepatitis B (HBV) recurrence posttransplant but is expensive and inconvenient."3.73Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. ( Dan, YY; Lim, SG; Wai, CT; Yeoh, KG, 2006)
"Incomplete virological response to adefovir dipivoxil (ADV) has been observed in patients with lamivudine-resistant hepatitis B virus (HBV) infection and may be associated with developing resistance and disease progression."3.73Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. ( Berg, T; Feucht, HH; Hüppe, D; Möller, B; Sarrazin, C; Spengler, U; van Bömmel, F; Wiedenmann, B; Zöllner, B, 2006)
"We report the treatment outcome in six post-renal transplant patients with lamivudine-resistant hepatitis B virus (LR-HBV) infection using adefovir dipivoxil and followed for 6 to 18 months."3.73Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. ( Dassanayake, AS; de Silva, AP; de Silva, HJ; Manamperi, A, 2006)
"We report a patient whose cryoglobulinemic vasculitis recurred due to reactivation of lamivudine-resistant HBV."3.73Successful treatment with adefovir of one patient whose cryoglobulinemic vasculitis relapsed under lamivudine therapy and who was diagnosed to have HBV virologic breakthrough with YMDD mutations. ( Cakir, N; Midilli, K; Pamuk, ON; Umit, H, 2006)
" A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis."3.72Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003)
"3%) patients developed hepatitis B virus DNA breakthrough 47 and 53 months, respectively, after transplantation, but they remained well after treatment with adefovir."3.72Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. ( Fan, ST; Lai, CL; Liu, CL; Lo, CM; Wei, WI; Wong, J; Yong, BH, 2003)
"Emergence of lamivudine-resistant hepatitis B virus (HBV) is a major concern in human immunodeficiency virus (HIV) and HBV coinfected patients."3.72In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. ( Benhamou, Y; Cahour, A; Katlama, C; Lada, O; Poynard, T; Thibault, V, 2004)
"Hepatitis B virus (HBV) recurrence following liver transplantation (LTx) has been controllable primarily with the use of hepatitis B immune globulin (HBIg) and lamivudine (LAM)."3.72Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. ( De Medina, M; Madariaga, J; Montalbano, M; Neff, GW; Nery, C; Nery, J; O'brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, N; Tzakis, AG, 2004)
"Resistant hepatitis B virus (HBV) strains develop in 30% of liver transplant recipients treated with lamivudine within 2 years from the time of transplantation."3.72Tenofovir therapy for lamivudine resistance following liver transplantation. ( Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG, 2004)
"ADV is an effective rescue therapy for patients with lamivudine-resistant hepatitis B post-liver transplant."3.72Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. ( Da Costa, M; Dan, YY; Isaac, J; Lee, HL; Lee, KH; Lee, YM; Lim, SG; Mak, K; Prabhakaran, K; Sutedja, DS; Wai, CT; Wee, A, 2004)
"Adefovir dipivoxil (ADV) is a nucleoside analogue that inhibits wild-type hepatitis B virus (HBV) and lamivudine-resistant HBV mutants in vitro and in vivo."3.72Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. ( Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2004)
"Three HIV-infected patients with chronic hepatitis B (genotype A) were switched to adefovir therapy after unsuccessful lamivudine treatment."3.72Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. ( Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L, 2004)
"Failure of prophylaxis for hepatitis B virus (HBV) recurrence in liver transplant patients with HBV immunoglobulin (HBIG) or lamivudine or both can be associated with rapid development of liver failure."3.72Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin. ( Akay, S; Akyildiz, M; Karasu, Z; Tokat, Y, 2004)
" Lamivudine is safe and effective in liver transplant recipients with recurrent hepatitis B virus (HBV) infection caused by wild-type virus or failure of hepatitis B immunoglobulin therapy."3.71Treatment of recurrent hepatitis B infection in liver transplant recipients. ( Terrault, NA, 2002)
"Lamivudine-resistant hepatitis B virus (HBV) is found in about 15-32% of infected patients with or without co-infection with HIV-1 after 1 year of lamivudine therapy."3.71Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. ( Benhamou, Y; Bochet, M; Brosgart, C; Calvez, V; Fievet, MH; Fry, J; Gibbs, CS; Katlama, C; Namini, H; Poynard, T; Thibault, V; Vig, P, 2001)
"Oral adefovir dipivoxil (ADV) reduced viral load in transgenic mice expressing hepatitis B virus (HBV)."3.71Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. ( Julander, JG; Morrey, JD; Sidwell, RW, 2002)
" Hepatitis B immunoglobulin and adefovir dipivoxil were initiated."3.70Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. ( Gibbs, CS; Howard, T; Jacobsmeyer, S; Lamy, P; Murray, A; Peters, MG; Singer, G; Xiong, X, 1999)
"Our aim is to selectively deliver 9-(2-phosphonylmethoxyethyl)adenine (PMEA) to parenchymal liver cells, the primary site of hepatitis B virus (HBV) infection."3.70Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B. ( Balzarini, J; Biessen, EA; Bijsterbosch, MK; de Vrueh, RL; Rump, ET; van Berkel, TJ; van De Bilt, E; van Veghel, R, 2000)
"The therapeutic potential of the antiretroviral drug 9-(2-phosphonylmethoxyethyl)adenine (PMEA, adefovir) for the treatment of human immunodeficiency virus (HIV)- and human hepatitis B virus (HBV) infections is currently being explored in advanced clinical trials."3.70Mechanistic study on the cytostatic and tumor cell differentiation-inducing properties of 9-(2-phosphonylmethoxyethyl)adenine (PMEA, adefovir)-collected publications. ( Hatse, S, 2000)
"Among 3656 highly viremic mothers treated with TDF, hepatitis B virus DNA suppression to the levels <200,000 IU/mL at delivery was achieved in 34% to 100% of mothers."3.01The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B. ( Deng, Y; Pan, CQ; Park, J; Zhu, L, 2023)
" However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months."3.01Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. ( Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023)
" In conclusion, a combination of LAM and ADV initiated at the time of wait listing provides safe and effective protection against recurrent HBV infection without the high costs and inconvenience associated with long-term HBIG therapy."2.78Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. ( Angus, PW; Gane, EJ; McCaughan, GW; Patterson, S; Strasser, SI, 2013)
" In addition, the bioavailability of tenofovir dipivoxil fumarate was evaluated in healthy male fasted subjects after a single comparatively equivalent dose."2.77Relative bioavailability study of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy male fasted volunteers. ( Ding, Y; Jia, Y; Liu, W; Lu, C; Song, Y; Sun, X; Wen, A; Yang, J, 2012)
"Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern."2.77Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. ( Bozkaya, H; Cakaloglu, Y; Chatzikyrkou, C; Dalekos, GN; Erhardt, A; Großhennig, A; Gurel, S; Manns, MP; Mederacke, I; Wedemeyer, H; Yalcin, K; Yurdaydin, C; Zachou, K; Zeuzem, S, 2012)
"Adefovir resistance was detected in two patients."2.76Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. ( Deutsch, M; Ketikoglou, I; Manesis, EK; Manolakopoulos, S; Mela, M; Papatheodoridis, GV; Striki, A; Tzourmakliotis, D, 2011)
"Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus-1 (HIV-1) and hepatitis C virus."2.74Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. ( Avihingsanon, A; Bowden, S; Dore, GJ; Lewin, SR; Locarnini, SA; Marks, P; Matthews, G; Perelson, AS; Ribeiro, RM; Ruxrungtham, K, 2009)
"Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients."2.73Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. ( Benhamou, Y; Dominguez, S; Duvivier, C; Ingiliz, P; Katlama, C; Poynard, T; Thibault, V; Valantin, MA, 2008)
"The role of hepatocellular carcinoma (HCC) in HBV recurrence remains unclear."2.73Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. ( Brechot, C; Castaing, D; Dussaix, E; Fallot, G; Faria, LC; Ferrari, TC; Gigou, M; Guettier, C; Roche, B; Roque-Afonso, AM; Samuel, D; Sebagh, M, 2008)
" Adefovir dipivoxil (ADV) liquid suspension (GS-02-526), as a new form of oral ADV, not only has competent antiviral efficacy, but is also more convenient for patients with swallowing difficulties or patients with impaired renal function requiring dosage adjustment."2.50Liquid oral suspension adefovir dipivoxil (GS-02-526): an update on treatments for hepatitis B infection. ( Chen, EQ; Shi, Y; Tang, H; Wu, DB, 2014)
"Several drugs are available to treat hepatitis B."2.49Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. ( Bani-Sadr, F; de Vries-Sluijs, T; Dunn, D; Gilson, R; Jain, MK; Kuzushita, N; Mauss, S; Nüesch, R; Núñez, M; Peters, M; Pillay, D; Price, H; Reiberger, T; Stephan, C; Tan, L, 2013)
" For patients receiving HBIG and LAM, a lower frequency of HBV recurrence was associated with a high HBIG dosage (≥10,000 IU/day) versus a low HBIG dosage (<10,000 IU/day) during the first week after LT [3."2.47Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. ( Akriviadis, E; Cholongitas, E; Goulis, J; Papatheodoridis, GV, 2011)
"Five lamivudine patients were switched to tenofovir and in another one adefovir dipivoxil were added."2.46Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. ( Christodoulou, DK; Katsanos, KH; Tsianos, EV; Tsianos, VE; Vagias, I; Zervou, E; Zioga, H; Zois, CD, 2010)
" The long-term administration of hepatitis B immunoglobulin (HBIG) dramatically reduced this risk."2.45Liver transplantation for hepatitis B virus. Pre-emptive and peri-operative prophylaxis. ( Mas, A, 2009)
"In patients not requiring HAART, treatment of hepatitis B should preferably consist of drugs without activity against HIV, such as pegylated interferon or adefovir."2.44[Hepatitis B in patients with HIV infection]. ( Barreiro, P; García-Samaniego, J; Martín-Carbonero, L, 2008)
"Hepatitis A is an acute disease, while patients infected by hepatitis B and hepatitis C viruses are likely to develop chronical infections and severe complications (cancer, cirrhosis)."2.44[The ABC of viral hepatitis]. ( Van Bambeke, F, 2008)
" In the near future the most realistic therapeutic option for the majority of patients with CHB will be long-term use of these new, more potent antiviral drugs, if they can achieve good safety profiles while maintaining low resistance rates at affordable costs."2.43Drugs in development for hepatitis B. ( Buti, M; Esteban, R, 2005)
"In the past, an unacceptable HBV recurrence rate with a high rate of graft loss was noted."2.43Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. ( Schiff, ER; Schreibman, IR, 2006)
"Hepatitis B is a major public health problem in the world today."2.43Hepatitis B: the pathway to recovery through treatment. ( Hollinger, FB; Lau, DT, 2006)
"In patients with liver cirrhosis (Child B and C) only nucleos(t)ides should be used."2.43[Therapy of hepatitis B virus infection]. ( Trautwein, C, 2006)
"Lamivudine has been widely used in the management of HBV transplant patients."2.42Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. ( Burroughs, AK; Papatheodoridis, GV; Sevastianos, V, 2003)
"Lamivudine appears to be a safe and effective antiviral agent, which may improve or stabilize liver disease in selected patients with advanced cirrhosis and active HBV replication."2.42Management of patients with decompensated HBV cirrhosis. ( Fontana, RJ, 2003)
" However, the inexorable development of drug resistance to lamivudine has been a major clinical impediment to the long-term use of such treatment."2.42Early detection of hepatitis B drug resistance: implications for patient management. ( Sablon, E; Shapiro, F; Zoulim, F, 2003)
"Lamivudine is a safe drug with rare and generally mild side effects."2.42Current antiviral therapy for chronic hepatitis B. ( Lim, YS; Suh, DJ, 2004)
" The recommended dosage of tenofovir DF in adults is 300 mg/d PO; pharmacokinetic and efficacy studies in children are ongoing."2.41Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. ( Fung, HB; Piacenti, FJ; Stone, EA, 2002)
"Lamivudine resistance has been found to confer cross-resistance to some of these compounds and it is likely that resistance to newer antivirals may also develop during prolonged use."2.41Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. ( Delaney, WE; Locarnini, S; Shaw, T, 2001)
"HIV and hepatitis B are two of the most prevalent viruses globally, and despite readily available preventive treatments unforgiving treatment regimens still exist, such as daily doses of medicine that are challenging to maintain especially in poorer countries."1.72A nanofiber based antiviral (TAF) prodrug delivery system. ( Bhave, M; Dart, A; Kingshott, P; Limqueco, E; Lowe, NM; Ratner, DM; Roy, D; Srinivasan, S; Stayton, P; Vlaskin, V, 2022)
"Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV."1.48Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018)
"Mixed cryoglobulinemias were type II (88%) and type III (12%)."1.43Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC. ( Casarin, P; Castelnovo, L; Dal Maso, L; Gattei, V; Mauro, E; Mazzaro, C; Monti, G; Pozzato, G; Urraro, T; Zignego, AL, 2016)
"Hepatitis B virus recurrence within 12 months was 4."1.42Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation. ( Choi, GH; Choi, JS; Joo, DJ; Ju, MK; Kim, MS; Kim, SI; Lee, J; Lee, JG; Lee, JJ; Song, SH, 2015)
"This retrospective investigation carried out in Guangdong Province indicated that not only are anti-HBV drugs efficacious for blocking vertical transmission of HBV but also are safe for both mothers and infants when taken by fathers or mothers during the reproduction phases of insemination and pregnancy."1.40[Retrospective analysis of the efficacy and safety of anti-hepatitis B virus drugs taken during pregnancy in women from the Guangdong Province]. ( Chen, X; Gao, W; Li, D; Peng, J; Wen, F; Xia, J; Xu, C; Xu, M; Yao, Z, 2014)
"Lamivudine was initiated to treat the patient prior to transplantation."1.39Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report. ( Özenirler, S; Sucak, GT; Suyanı, E; Yaşar, DG, 2013)
"There was no mortality due to HBV recurrence."1.39Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. ( Goyal, N; Gupta, S; Kumar, A; Taneja, S; Wadhawan, M, 2013)
"Telbivudine seemed to be a candidate for exclusive anti-HBV therapy because it exerts no significant in vitro activity against HIV."1.39In vivo antiviral activity of telbivudine against HIV-1: a case report. ( Bonadies, G; Borgia, G; Borrelli, F; Buonomo, AR; Carleo, MA; Gentile, I; Portella, G, 2013)
"The median time to HBV recurrence after transplantation was 31."1.38[Prognosis analysis of hepatitis B virus recurrence after liver transplantation: a single-center study of 38 cases]. ( Deng, YL; Gao, W; Jiang, WT; Qu, W; Rao, W; Shen, ZY; Sun, LY; Sun, XY; Zhang, JJ; Zhang, YM; Zhu, ZJ, 2012)
"Primary outcomes were major birth defects rates with exposure to all antivirals, individual classes, and drugs compared to population-based controls."1.38Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. ( Aguilar, C; Brown, RS; Buti, M; Fagan, EA; Leu, CS; Pereira, MR; Tilson, HH; Verna, EC, 2012)
" The lead candidates, both 1a (PBHBV-001) and 3c (PBHBV-2-15), were well-tolerated in both normal and HBV-transgenic mice and exhibited acceptable pharmacokinetics and bioavailability in Sprague-Dawley rats."1.37Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. ( Block, TM; Clearfield, E; Cuconati, A; Goddard, C; Guo, H; Mills, C; Morrey, JD; Motter, NE; Xiao, T; Xu, X; Yu, W; Zhao, K, 2011)
"Hepatitis B is a DNA virus affecting hundreds of millions of individuals worldwide."1.36Viral resistance in hepatitis B: prevalence and management. ( Chee, GM; Poordad, F, 2010)
" Mean HBIg half-life was 21."1.36Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. ( Andreone, P; Bacci, M; Burra, P; Canova, D; Cursaro, C; Fiorentino, B; Guazzini, S; Marengo, A; Marzano, A; Riili, A; Volpes, R, 2010)
" Individualized dosing intervals should be further evaluated as a cost-effective alternative to fixed dosing schemes."1.35Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. ( Hadem, J; Hooman, N; Klempnauer, J; Manns, MP; Philipp, G; Priess, A; Rifai, K; Rosenau, J; Tillmann, HL; Vaske, B, 2008)
"We report a case of autoimmune thrombocytopenia associated with acute reverse seroconversion of hepatitis B in a patient who was initially hepatitis B virus surface antigen negative and hepatitis B virus surface antibody positive."1.34[Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation]. ( Aubourg, A; Bacq, Y; d'Alteroche, L; Gaudy, C; Senecal, D, 2007)
"Adefovir dipivoxil (AD) is a nucleotide analogue of adenosine that has achieved significant results in virologic, biochemical, and clinical parameters in lamivudine-resistant HBV-infected patients."1.33Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. ( Barrios Peinado, C; Cuervas-Mons Martínez, V; Herreros de Tejada Echanojáuregui, A; López Monclús, J; Lucena de la Poza, JL; Moreno Planas, JM; Portero Azorin, F; Revilla Negro, J; Rubio González, E; Sánchez Turrión, V, 2005)
"Treatment with lamivudine is initially efficient in both infections but the incidence of lamivudine-resistant HBV emergence increases over time."1.33Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. ( Avilés, JF; Bárcena, R; Barrios, C; Buti, M; Casanovas, T; Cuervas, V; De la Mata, M; Del Campo, S; Delgado, M; Dieguez, ML; Fraga, E; Gonzalez, A; Herrero, JI; Loinaz, C; Mas, A; Moraleda, G; Moreno, JM; Muñoz, R; Otero, A; Prieto, M; Rueda, M; Sousa, JM, 2005)
"We describe an acute hepatitis D virus superinfection in an HIV-1-infected patient under HAART treatment who was previously a chronic carrier of a surface negative HBV variant resistant to lamivudine."1.33Hepatitis delta virus super-infection in a co-infected patient with the human immunodeficiency virus type 1 and a surface antigen-negative hepatitis B virus variant. ( Alloui, C; Bouhassoune, K; Calboreanu, A; Dény, P; Gordien, E; Legal, F; Podevin, P; Rico-Garcia, M; Salmon-Céron, D; Sogni, P, 2006)
"Adefovir has been shown to be effective in the treatment of lamivudine-resistant HBV in HIV/HBV-coinfected patients."1.32Antiretroviral therapy and HIV/hepatitis B virus coinfection. ( Benhamou, Y, 2004)
"Adefovir dipivoxil is a prodrug of adefovir designed to enhance its oral bioavailability."1.31Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. ( Brown, C; Cullen, JM; Cundy, KC; Eisenberg, EJ; Gibbs, C; Li, DH; Toole, J; Wolfe, J, 2001)
"Adefovir was administered for six consecutive days starting one day before or four days after DHBV inoculation."1.31Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. ( Delmas, J; Gibbs, C; Hantz, O; Jamard, C; Schorr, O; Trépo, C; Zoulim, F, 2002)

Research

Studies (382)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (2.62)18.2507
2000's179 (46.86)29.6817
2010's169 (44.24)24.3611
2020's24 (6.28)2.80

Authors

AuthorsStudies
Yeh, ML1
Liang, PC1
Trinh, S1
Huang, CI1
Huang, CF1
Hsieh, MY1
Huang, JF1
Dai, CY1
Chuang, WL2
Nguyen, MH1
Yu, ML1
Zeng, QL1
Zhang, HX1
Zhang, JY2
Huang, S1
Li, WZ1
Li, GM1
Pan, YJ1
Feng, YH1
Li, ZQ1
Zhang, GF1
Xu, JH1
Lin, WB1
Xu, GH1
Liu, N1
Zhang, GQ1
Li, GT1
Li, W4
Zeng, YL1
Song, N1
Wang, M1
Zhang, DW1
Chen, ZM1
Cui, GL1
Li, J11
Lv, J1
Liu, YM1
Liang, HX1
Sun, CY1
Zhou, YH1
Yu, ZJ1
Wang, FS1
Dart, A1
Roy, D1
Vlaskin, V1
Limqueco, E1
Lowe, NM1
Srinivasan, S1
Ratner, DM1
Bhave, M1
Stayton, P1
Kingshott, P1
Kishimoto, M1
Komine, M1
Kamiya, K1
Sugai, J1
Kuwahara, A1
Morimoto, N1
Ohtsuki, M1
Cui, H1
Rong, W1
Ma, J1
Zhu, Q1
Jiang, B1
Zhang, L5
Li, C4
Zhuo, Z1
Chen, M2
Roediger, R1
Smyth, EK1
Dieterich, D1
Kayes, T1
Crane, H1
Symonds, A1
Dumond, J1
Cottrell, M1
Di Girolamo, J1
Manandhar, S1
Lim, TH1
Gane, E3
Kashuba, A2
Levy, MT3
Arnouk, S1
Whitsett, M1
Papadopoulos, J1
Stewart Lewis, Z1
Dagher, NN1
Feldman, DM1
Park, JS1
Dong, H2
Hong, X1
He, Y3
Bao, Z1
Zhang, Y8
Shen, S1
Wang, G1
Zhang, J6
Mo, R1
Kumar, M1
Jung, CY1
Kim, HW1
Lee, JI2
Lee, HW1
Ahn, SH4
Kim, SU2
Kim, BS1
Suda, G1
Baba, M1
Yamamoto, Y1
Sho, T1
Ogawa, K1
Kimura, M1
Hosoda, S1
Yoshida, S1
Kubo, A1
Fu, Q1
Yang, Z3
Tokuchi, Y1
Kitagataya, T1
Maehara, O1
Ohnishi, S1
Yamada, R1
Ohara, M1
Kawagishi, N1
Natsuizaka, M1
Nakai, M1
Morikawa, K1
Furuya, K1
Suzuki, K1
Izumi, T1
Meguro, T1
Terashita, K1
Ito, J1
Kobayashi, T1
Tsunematsu, I1
Sakamoto, N1
Zhu, L2
Park, J1
Deng, Y1
Pan, CQ3
Cheng, CH1
Hung, HC1
Lee, JC1
Wang, YC1
Wu, TH1
Lee, CF1
Wu, TJ1
Chou, HS1
Chan, KM1
Lee, WC1
Hwang, EG1
Jung, EA1
Yoo, JJ1
Kim, SG1
Kim, YS2
Liu, Z4
Zhao, Z1
Ma, X2
Liu, S2
Xin, Y1
Duan, YQ1
Hu, P1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L2
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y3
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S2
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q5
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X6
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J5
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z2
Zhu, J2
Jiang, H2
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K3
Li, X9
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y5
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L4
Shao, J1
Sun, M1
Xu, G1
Zhang, X10
Xu, N1
Wang, R1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L4
Yang, X1
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H6
Yao, L2
Sun, L3
Zhu, Z2
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH5
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S2
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C3
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C4
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y12
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M3
An, Z1
Jiang, J2
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y15
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH2
Choi, J1
Lim, YS4
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L2
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J3
Chu, S1
Pan, Q1
Li, D3
Zheng, S3
Ma, L1
Wang, L5
Hu, T1
Wang, F1
Han, Z2
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y4
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y6
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM2
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Guo, W1
Liu, M2
Liu, T6
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L3
Shi, X1
Kang, S1
Duan, W1
Zhang, S3
Feng, J3
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Jiang, X3
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J2
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W3
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y2
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X5
Cao, Q1
Yuan, X1
Nie, W1
Yang, J3
Shao, B1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H3
Cui, Y1
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X4
Huang, Y4
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y2
Huang, M3
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL2
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ2
Kang, J1
Park, S2
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI2
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E4
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z3
Liang, H1
Xu, X2
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M2
Wu, J1
Cai, S1
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J3
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J2
Wu, P1
Xu, L2
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY2
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L2
Tan, SJ1
Xin, S4
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D5
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC2
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X2
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X2
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Fang, Q1
Chen, H1
Kim, GW1
Imam, H1
Khan, M1
Siddiqui, A1
Hui, PW1
Ng, C1
Cheung, KW1
Lai, CL5
Surial, B1
Béguelin, C1
Chave, JP1
Stöckle, M1
Boillat-Blanco, N1
Doco-Lecompte, T1
Bernasconi, E1
Fehr, J1
Günthard, HF1
Schmid, P1
Walti, LN1
Furrer, H1
Rauch, A1
Wandeler, G1
Kalkeri, R1
Ptak, RG1
Zhou, T1
Van Mellaert, L1
Dumbre, SG1
Block, T1
Groaz, E1
De Jonghe, S1
Herdewijn, P1
Yoshida, K1
Enomoto, M4
Tamori, A3
Nishiguchi, S3
Kawada, N2
Tedeschi, A2
Frustaci, AM1
Mazzucchelli, M1
Cairoli, R1
Montillo, M1
Abdelbary, GA1
Amin, MM1
Zakaria, MY1
El Awdan, SA1
Lin, J1
Zhuo, Y1
Zhang, D2
Kim, WI1
Cho, DH1
Kim, YJ1
Kim, HS2
Kim, JH3
Cha, SK1
Park, KS1
Lee, SM1
Shi, H2
Xia, J2
Chan, L1
Asriel, B1
Eaton, EF1
Wyatt, CM1
Molica, S1
Levato, L1
Mirabelli, R1
Lentini, M1
Hammond, SP1
Chen, K1
Pandit, A1
Davids, MS1
Issa, NC1
Marty, FM1
Cho, J1
Cheung, PP1
Agarwal, K1
Brunetto, M1
Seto, WK1
Fung, S1
Marcellin, P6
Izumi, N1
Bae, H1
Sharma, M1
Janssen, HLA1
Çelen, MK2
Furusyo, N1
Shalimar, D1
Yoon, KT1
Trinh, H1
Flaherty, JF1
Gaggar, A1
Lau, AH1
Cathcart, AL1
Bhardwaj, N1
Suri, V1
Mani Subramanian, G1
Gane, EJ2
Buti, M4
Chan, HLY1
Alsunaid, SR1
Ashraf, H1
Soubani, AO1
Delgado Ramos, GM1
Almaddah, N1
Alsafwah, S1
Yu, F1
Naing, C1
Poovorawan, Y1
Tong, KS1
Tsai, WC1
Hsu, WT1
Liu, WD1
Sun, HY1
Chuang, YC1
Huang, YS1
Cheng, A2
Lin, KY1
Huang, YC1
Chen, GJ1
Huang, SH1
Sheng, WH1
Hsieh, SM1
Hung, CC1
Chang, SC1
Innocenti, I1
Morelli, F1
Autore, F1
Corbingi, A1
Pasquale, R1
Sorà, F1
Pompili, M1
Laurenti, L1
Li, T1
Qu, Y1
Lin, C1
Yang, B1
Kunii, T1
Iijima, T1
Jojima, T1
Shimizu, M1
Kase, M1
Sakurai, S1
Kogai, T1
Usui, I1
Aso, Y1
Neumann-Fraune, M2
Beggel, B1
Pfister, H1
Kaiser, R2
Verheyen, J2
Marzano, A2
Marengo, A2
David, E1
Rizzetto, M1
Patterson, S1
Strasser, SI2
McCaughan, GW2
Angus, PW3
Gatanaga, H2
Hayashida, T1
Tanuma, J1
Oka, S3
Yaşar, DG1
Suyanı, E1
Özenirler, S1
Sucak, GT1
Chang, MS3
Olsen, SK3
Pichardo, EM3
Heese, S2
Stiles, JB3
Guarrera, JV3
Emond, JC3
Brown, RS5
Rosenthal-Cogan, L1
Brubaker, WD1
Casals-Seoane, F1
Arberas-Díez, B1
García-Buey, L1
Antonucci, G1
Mazzotta, F2
Angeletti, C1
Girardi, E1
Puoti, M2
De Stefano, G1
Grossi, P1
Petrosillo, N1
Pagano, G1
Cassola, G1
Orani, A1
Sagnelli, C2
Armignacco, O2
Sagnelli, E2
McGonigal, KH1
Bajjoka, IE1
Abouljoud, MS1
Wadhawan, M1
Gupta, S1
Goyal, N1
Taneja, S1
Kumar, A1
Cento, V1
Van Hemert, F1
Mirabelli, C1
Di Maio, VC1
Salpini, R1
Bertoli, A1
Micheli, V2
Gubertini, G1
Romano, S1
Visca, M1
De Sanctis, GM1
Berkhout, B1
Marino, N1
Cappiello, G1
Spanò, A1
Sarrecchia, C1
Ceccherini-Silberstein, F1
Andreoni, M1
Angelico, M1
Perno, CF1
Svicher, V1
Lv, GC1
Yao, JM1
Yang, YD2
Zheng, L2
Sheng, JF1
Chen, Y2
Li, LJ2
Jia, YY1
Lu, CT1
Zhao, JY1
Wang, S1
Wen, AD1
Yang, ZF1
Hang, TJ1
Price, H1
Dunn, D1
Pillay, D1
Bani-Sadr, F2
de Vries-Sluijs, T1
Jain, MK3
Kuzushita, N1
Mauss, S3
Núñez, M2
Nüesch, R1
Peters, M1
Reiberger, T2
Stephan, C1
Tan, L1
Gilson, R2
Gulland, A1
Hamers, RL1
Zaaijer, HL2
Wallis, CL1
Siwale, M1
Ive, P1
Botes, ME1
Sigaloff, KC1
Hoepelman, AI1
Stevens, WS1
Rinke de Wit, TF1
Gentile, I1
Bonadies, G1
Carleo, MA1
Buonomo, AR1
Borrelli, F1
Portella, G1
Borgia, G1
Su, Y1
Min, L1
Lian, JS1
Zeng, LY1
Chen, JY1
Jia, HY1
Zhang, YM2
Xiang, DR1
Hu, JH1
Lu, YF1
Miller, MD3
Kitrinos, KM2
Kim, MN1
Lee, CK3
Lee, S1
Kim, DY3
Han, KH3
Chon, CY2
Park, JY2
Calvaruso, V1
Craxì, A1
Mert, D1
Ay, M1
Dal, T1
Kaya, S1
Yildirim, N1
Gulsun, S1
Barcin, T1
Kalkanli, S1
Dal, MS1
Ayaz, C1
Wright, AJ1
Fishman, JA1
Chung, RT1
Shahabadi, N1
Falsafi, M1
Rodríguez Gil, FJ1
Gallego Pérez, B1
Gajownik, U1
García Belmonte, D1
Marín Bernabé, CM1
Martínez Crespo, JJ1
Hafkin, JS1
Osborn, MK1
Localio, AR1
Amorosa, VK1
Kostman, JR1
Stern, JJ1
De La Torre, P1
Mounzer, K1
Frank, I1
Gross, R1
Chang, KM1
Lo Re, V1
Hamnvik, OP1
Becker, CB1
Levy, BD1
Loscalzo, J1
Kang, M1
Hollabaugh, K1
Pham, V1
Koletar, SL1
Wu, K1
Smurzynski, M1
Aberg, JA1
Xu, Z4
Pisaturo, M1
Martini, S1
Filippini, P1
Coppola, N1
Greenup, AJ1
Tan, PK1
Nguyen, V1
Glass, A1
Davison, S1
Chatterjee, U1
Holdaway, S1
Samarasinghe, D1
Jackson, K1
Locarnini, SA3
Rao, W2
Xie, M1
Shen, Z1
Tsai, PJ1
Chang, A1
Yamada, S1
Tsai, N1
Bartholomew, ML1
Viganò, M4
Mangia, G1
Lampertico, P4
Chen, EQ1
Shi, Y1
Wu, DB1
Wu, L1
Jin, Y1
Jia, J1
Li, M1
Watanabe, T2
Tokumoto, Y1
Hirooka, M1
Koizumi, Y1
Tada, F1
Ochi, H2
Abe, M2
Kumagi, T1
Ikeda, Y1
Matsuura, B1
Takada, K1
Hiasa, Y1
Barone, M1
Iannone, A1
Di Leo, A1
Woo, HY1
Choi, JY1
Yoon, SK1
Suh, DJ3
Paik, SW2
Um, SH2
Kim, BI1
Lee, HJ1
Cho, M1
Kim, DJ1
Hwang, JS1
Roche, B2
Samuel, D5
Koskinas, JS1
Deutsch, M2
Adamidi, S1
Skondra, M1
Tampaki, M1
Alexopoulou, A1
Manolakopoulos, S2
Pectasides, D1
Huang, G1
Lau, WY1
Wang, ZG1
Pan, ZY1
Yuan, SX1
Shen, F1
Zhou, WP1
Jiao, M1
Ren, F1
Wen, T1
Wei, L2
Bai, L1
Han, Y1
Zhao, C1
Duan, Z1
Peng, J1
Xu, M1
Yao, Z1
Wen, F1
Gao, W2
James, G1
Sidhu, P1
Raza, M1
Cho, YK1
Cui, XJ1
Jeong, SU1
Song, BC1
Rosenthal, P2
Ehrhardt, S1
Xie, C1
Guo, N1
Nelson, K1
Thio, CL1
Jiao, Z1
Yan, L1
Hamada-Tsutsumi, S1
Yokomaku, Y1
Imamura, J1
Sugiura, W1
Tanaka, Y1
Hakim, GD1
Akarsu, M1
Karademir, S1
Unek, T1
Astarcıoğlu, İ1
Utsumi, T1
Sawada, K1
Nakajima, S1
Ohtake, T1
Fujiya, M1
Kohgo, Y1
Choudhary, NS1
Saraf, N1
Saigal, S1
Mohanka, R1
Rastogi, A1
Goja, S1
Menon, PB1
Soin, AS1
Hong, SP3
Jang, ES1
Park, SJ1
Hwang, SG1
Kang, SK1
Jeong, SH1
Singer, GA1
Zielsdorf, S1
Fleetwood, VA1
Alvey, N1
Cohen, E1
Eswaran, S1
Shah, N1
Chan, EY1
Hertl, M1
Fayek, SA1
Jiang, W1
Liu, LQ1
Guan, GJ1
Liu, XC1
Khemichian, S1
Hsieh, MJ1
Zhang, SR1
Limurti, J1
Kim, J2
Fong, TL1
Wang, YW1
Shan, X1
Deng, H1
Huang, WX1
Zhang, DZ1
Tang, N1
Shan, YL1
Guo, JJ1
Huang, A1
Su, F1
Dai, J1
Cui, X1
Ning, H1
Ye, X1
Chen, R1
Ye, H1
Cheng, S1
Soriano, V3
Barreiro, P3
de Mendoza, C1
Rawal, RK1
Konreddy, AK1
Chu, CK1
Lee, JG1
Lee, J1
Song, SH1
Ju, MK1
Kim, MS1
Choi, JS1
Joo, DJ1
de Jésus Ngoma, P1
Kabamba, B1
Dahlqvist, G1
Sempoux, C1
Lanthier, N1
Shindano, T1
Van Den Neste, E1
Horsmans, Y1
Murray, JM1
Stancevic, O1
Lütgehetmann, M3
Wursthorn, K2
Petersen, J4
Dandri, M2
Wang, JH2
Wang, XY1
Fei, R1
Zhang, HY2
Mazzaro, C1
Dal Maso, L1
Urraro, T1
Mauro, E1
Castelnovo, L1
Casarin, P1
Monti, G1
Gattei, V1
Zignego, AL1
Pozzato, G1
Zhang, MY1
Zhu, GQ1
Shi, KQ1
Zheng, JN1
Cheng, Z1
Zou, ZL1
Huang, HH1
Chen, FY1
Zheng, MH1
Gallant, J1
Brunetta, J1
Crofoot, G1
Benson, P1
Mills, A1
Brinson, C1
Garner, W1
Fordyce, M1
Das, M1
McCallister, S1
Herishanu, Y1
Katchman, H1
Polliack, A1
Li, DF1
Jin, ZJ1
Chen, YS1
Qiao, LM1
Zhou, J1
Quiros-Roldan, E1
Calabresi, A1
Lapadula, G1
Tirelli, V1
Costarelli, S1
Cologni, G1
Zaltron, S1
Carosi, G1
Torti, C1
Yang, DH1
Xie, SF1
Wang, YM1
Zhao, NF1
Li, MW1
Lo, YL1
See, SJ1
Tan, CK1
Kuwahara, R2
Kumashiro, R2
Ide, T2
Koga, Y2
Hino, T2
Hisamochi, A1
Tanaka, K1
Ogata, K1
Koga, H1
Takao, Y1
Sata, M2
Matthews, GV3
Avihingsanon, A2
Lewin, SR3
Amin, J1
Rerknimitr, R1
Petcharapirat, P1
Marks, P2
Sasadeusz, J3
Cooper, DA2
Bowden, S2
Locarnini, S6
Ruxrungtham, K2
Dore, GJ4
Kamar, N1
Milioto, O1
Alric, L1
El Kahwaji, L1
Cointault, O1
Lavayssière, L1
Sauné, K1
Izopet, J1
Rostaing, L1
Lacombe, K2
Gozlan, J2
Boyd, A2
Boelle, PY1
Bonnard, P1
Molina, JM2
Miailhes, P1
Lascoux-Combe, C1
Serfaty, L2
Zoulim, F6
Girard, PM2
Beckebaum, S1
Sotiropoulos, GC1
Gerken, G1
Cicinnati, VR1
Patterson, SJ2
Renou, C1
Cadranel, JF1
Pariente, A1
Pénaranda, G1
Bourlière, M1
Halfon, P1
Igual, JP1
Harafa, A1
Muller, P1
Bertrand, JJ1
Laugier, R1
Degertekin, B2
Hussain, M2
Tan, J3
Oberhelman, K2
Lok, AS8
Ingiliz, P2
Valantin, MA1
Thibault, V4
Duvivier, C1
Dominguez, S1
Katlama, C4
Poynard, T4
Benhamou, Y6
García Buey, L1
González Mateos, F1
Moreno Otero, R1
Martín-Carbonero, L1
García-Samaniego, J2
Ribeiro, RM2
Matthews, G1
Perelson, AS2
Audsley, J1
Arrifin, N1
Yuen, LK1
Ayres, A1
Crowe, SM1
Bartholomeusz, A2
Mijch, A1
Kwon, HC1
Cheong, JY1
Cho, SW1
Choi, JM1
Kim, SO1
Yoo, WD1
Kurbegov, AC1
Sokol, RJ1
Alvarez-Uria, G1
Ratcliffe, L1
Vilar, J1
Pastor, R1
Habersetzer, F1
Fafi-Kremer, S1
Doffoel, M1
Baumert, TF1
Gut, JP1
Stoll-Keller, F1
Schvoerer, E1
Amini-Bavil-Olyaee, S1
Herbers, U1
Sheldon, J3
Luedde, T1
Trautwein, C4
Tacke, F2
Jalili, A1
Kinaciyan, T1
Barisani, T1
Peck-Radosavljevic, M2
Stingl, G1
Geusau, A1
Wöhrl, S1
Margeridon-Thermet, S2
Shulman, NS1
Ahmed, A1
Shahriar, R1
Holmes, SP2
Babrzadeh, F1
Gharizadeh, B1
Hanczaruk, B1
Simen, BB1
Egholm, M1
Shafer, RW2
Schildgen, O3
Moucari, R2
Francoz, C1
Lada, O3
Abdel Razek, W1
Valla, D1
Belghiti, J1
Durand, F1
Tan, LK1
Gilleece, Y1
Mandalia, S1
Murungi, A1
Grover, D1
Fisher, M1
Atkins, M1
Nelson, M2
Rodríguez Dominguez, M1
de la Loma, GA1
Moreira Vicente, V2
Mateos Lindemann, M1
Mas, A2
Terrault, NA3
Tran, TT1
Schiff, E2
McGuire, BM1
Tupper, R1
Ramanathan, S1
Enejosa, J1
Zhong, L1
Zong, J1
Wang, YZ1
Xiao, JH1
Ruan, LH1
Pu, XK1
Shen, HY1
Wu, GX1
Laurent, C1
Bourgeois, A1
Mpoudi-Ngolé, E1
Kouanfack, C1
Ciaffi, L1
Nkoué, N1
Mougnutou, R1
Calmy, A1
Koulla-Shiro, S1
Ducos, J1
Delaporte, E1
Kobayashi, S1
Iwai, S1
Morikawa, H1
Sakaguchi, H1
Habu, D1
Shiomi, S1
Imanishi, Y1
Zhang, FK1
Jia, JD1
Wang, BE1
Fujimoto, M1
Ichikawa, T1
Nakao, K1
Miyaaki, H1
Shibata, H1
Eguchi, S1
Takatsuki, M1
Nagaoka, S1
Yatsuhashi, H1
Kanematsu, T1
Eguchi, K1
Taéron, C1
Vassiliadis, TG1
Giouleme, O1
Koumerkeridis, G1
Koumaras, H1
Tziomalos, K1
Patsiaoura, K1
Grammatikos, N1
Mpoumponaris, A1
Gkisakis, D1
Theodoropoulos, K1
Panderi, A1
Katsinelos, P1
Eugenidis, N1
Kurashige, N1
Ohkawa, K1
Hiramatsu, N1
Oze, T1
Yakushijin, T1
Mochizuki, K1
Hosui, A1
Miyagi, T1
Ishida, H1
Tatsumi, T1
Kanto, T1
Takehara, T1
Hayashi, N1
Mansour, W1
Ducancelle, A1
Le Gal, F1
Le Guillou-Guillemette, H1
Abgueguen, P1
Pivert, A1
Calès, P1
Gordien, E2
Lunel, F1
van Bömmel, F6
de Man, RA3
Wedemeyer, H5
Deterding, K2
Buggisch, P2
Erhardt, A2
Hüppe, D3
Stein, K1
Trojan, J2
Sarrazin, C2
Böcher, WO1
Spengler, U2
Wasmuth, HE2
Reinders, JG1
Möller, B3
Rhode, P1
Feucht, HH3
Wiedenmann, B2
Berg, T7
Katz, LH2
Paul, M2
Guy, DG2
Tur-Kaspa, R2
Gervain, J2
Horváth, G2
Hunyady, B2
Makara, M2
Pár, A2
Szalay, F2
Tornai, I2
Telegdy, L2
Wei, ZW1
Xu, QH1
Shu, X1
Jie, YS1
Zhang, K1
Xie, QF1
Li, G1
Genzini, T1
Dos Santos, RG1
Pedrosa, C1
Curvelo, LA1
Noujaim, HM1
Crescentini, F1
Mota, LT1
Guirro, TG1
Ferreira, FY1
Salomão, P1
Pereira, JR1
de Miranda, MP1
Poordad, F1
Chee, GM1
Jiang, L1
Yan, LN1
Jang, H1
Choi, JJ1
Son, Y1
Park, H1
Xu, T1
Si, L1
Ren, X1
Zhong, Y2
Zhao, J2
Coffin, CS1
Mulrooney-Cousins, PM1
Peters, MG2
van Marle, G1
Roberts, JP1
Michalak, TI1
Mendes-Correa, MC1
Pinho, JR1
Yuen, L1
Sitnik, R1
Santana, RA1
Gomes-Gouvêa, MS1
Leite, OM1
Martins, LG1
Silva, MH1
Gianini, RJ1
Uip, DE1
Wu, ZP1
Hang, T1
Gao, YT1
Jing, L1
Liu, L2
Du, Z1
Wong, VW1
Li, Q1
Reuman, EC1
Caudill, HB1
Borroto-Esoda, K4
Svarovskaia, ES1
Jiménez-Pérez, M1
Sáez-Gómez, AB1
Mongil Poce, L1
Lozano-Rey, JM1
de la Cruz-Lombardo, J1
Rodrigo-López, JM1
Thurairajah, P1
Khanna, A1
Mutimer, D2
Brost, S1
Schnitzler, P1
Stremmel, W1
Eisenbach, C1
Katsanos, KH1
Tsianos, VE1
Zois, CD1
Zioga, H1
Vagias, I1
Zervou, E1
Christodoulou, DK1
Tsianos, EV1
Karlas, T1
Hartmann, J1
Weimann, A1
Maier, M1
Bartels, M1
Jonas, S1
Mössner, J1
Tillmann, HL5
Wiegand, J2
Andreone, P2
Volpes, R1
Canova, D1
Cursaro, C2
Riili, A1
Fiorentino, B1
Bacci, M1
Guazzini, S1
Burra, P1
Mallet, V1
Vallet-Pichard, A1
Pol, S3
Andersen, ES1
Weiland, O1
Leutscher, P1
Krarup, H1
Westin, J1
Moessner, B1
Konopski, Z1
Frigstad, SO1
Kjær, M1
Christensen, PB1
Weis, N1
Lei, J1
Gao, Z1
Diamanti, A1
Sartorelli, MR1
Alterio, A1
Comparcola, D1
Corsetti, T1
Iacono, A1
Pizzichemi, G1
Nobili, V1
de Ville de Goyet, J1
Torre, G2
Cholongitas, E3
Goulis, J1
Akriviadis, E2
Papatheodoridis, GV4
Numata, A1
Akimoto, T1
Toshima, M1
Iwazu, Y1
Otani, N1
Miki, T1
Sugase, T1
Saito, O1
Hamano, Y1
Takemoto, F1
Ueda, Y1
Muto, S1
Kusano, E1
Milazzo, L1
Corbellino, M1
Foschi, A1
Dodero, A1
Mazzocchi, A1
Montefusco, V1
Zehender, G1
Antinori, S1
Yu, W1
Goddard, C1
Clearfield, E1
Mills, C1
Xiao, T1
Guo, H1
Morrey, JD2
Motter, NE1
Block, TM1
Cuconati, A1
Giles, M1
Visvanathan, K1
Schirmer, P1
Winters, M1
Holodniy, M1
Striki, A1
Mela, M1
Ketikoglou, I1
Tzourmakliotis, D1
Manesis, EK1
Gervais, A1
Branger, M1
Peytavin, G1
Roquebert, B1
Collin, G1
Fraqueiro, G1
Hamet, G1
Martinot-Peignoux, M1
Matheron, S1
Zachou, K2
Dalekos, GN2
García-Alonso, FJ1
Martín-Mateos, RM1
Maylin, S1
Delaugerre, C1
Lavocat, F1
Simon, F1
Singal, AK1
Fontana, RJ3
Fu, XZ1
Pei, JY1
Zhou, W1
Lan, YY1
Wang, AM1
Stravitz, RT1
Shiffman, ML2
Kimmel, M1
Puri, P1
Luketic, VA2
Sterling, RK2
Sanyal, AJ2
Cotterell, AH1
Posner, MP2
Fisher, RA2
Chen, CH1
Lu, SN1
Hu, TH1
Hung, CH1
Chang, MH1
Changchien, CS1
Lee, CM1
Kumar, N1
Bower, M1
Ujhelyi, E1
Lu, C1
Jia, Y1
Ding, Y1
Wen, A1
Abdelmessih, R1
Verna, EC2
Son, CY1
Ryu, HJ1
Lee, JM1
Lee, MH1
Qu, W1
Sun, LY1
Zhu, ZJ1
Deng, YL1
Sun, XY1
Zhang, JJ1
Jiang, WT1
Shen, ZY1
Mi, LJ1
Bunchorntavakul, C1
Karsdon, J1
Huang, WM1
Singhvi, G1
Ghany, MG1
Reddy, KR1
Mederacke, I1
Yurdaydin, C2
Großhennig, A1
Cakaloglu, Y1
Yalcin, K1
Gurel, S1
Zeuzem, S3
Chatzikyrkou, C1
Bozkaya, H1
Manns, MP5
Vasiliadis, T1
Antoniadis, N1
Goulis, I1
Papanikolaou, V1
Pereira, MR1
Tilson, HH1
Aguilar, C1
Leu, CS1
Fagan, EA1
Zoutendijk, R1
de Vries-Sluijs, TE2
Reijnders, JG2
Mulder, JW1
Kroon, FP2
Richter, C1
van der Eijk, AA3
Sonneveld, MJ1
Hansen, BE2
van der Ende, ME2
Janssen, HL2
Psevdos, G1
Sharp, V1
Hall, AM1
Bock, FJ1
Dai, CL1
Zhu, M1
Wang, BP1
Guo, F1
Song, WZ1
Zhu, TH1
Wang, BL1
Qiu, MC1
Boxall, E1
Sira, J1
Kaskar, S1
Workman, J1
Kelly, D1
Babiker, ZOE1
Hogan, C1
Ustianowski, A1
Wilkins, E1
Schinazi, RF2
Bassit, L1
Clayton, MM2
Sun, B2
Kohler, JJ1
Obikhod, A1
Arzumanyan, A1
Feitelson, MA2
Baxa, DM1
Thekdi, AD1
Golembieski, A1
Krishnan, PV1
Sharif, O1
Kizy, A1
Shetron-Rama, L1
Jovanovich, J1
Chappell, BJ1
Snow-Lampart, A1
Gordon, SC1
Kosi, L1
Payer, BA1
Grabmeier-Pfistershammer, K1
Strassl, R1
Rieger, A1
Kinai, E1
Hosokawa, S1
Gomibuchi, H1
Kikuchi, Y1
Morando, F1
Rosi, S1
Fasolato, S1
Cavallin, M1
Gola, E1
Gatta, A1
Angeli, P1
Du, Y1
Shen, QC1
Huang, AL1
Zheng, MY1
Jiang, HL1
Qin, B1
Budeus, B1
Cao, L1
Wu, C1
Rayner, S1
Hoffmann, D1
Yim, HJ1
Seo, YS1
Yoon, EL1
Kim, CW1
Lee, CD1
Park, SH1
Lee, MS1
Park, CK1
Chae, HB1
Kim, MY1
Baik, SK1
Lee, JW1
Feeney, SA1
McCaughey, C1
Watt, AP1
Agnaf, MR1
McDougall, N1
Wend, UC1
Gerlich, WH1
Coyle, PV1
Patrick, I1
Krznaric, I1
Ivanka, K1
Obermeier, M1
Martin, O1
Tufano, M1
Liccardo, D1
Riva, S1
Candusso, M1
Iorio, R1
Wünsche, T1
Schürmann, D1
Dieterich, DT1
Fung, HB1
Stone, EA1
Piacenti, FJ1
Tubiana, R1
Bock, CT2
Bleck, JS1
Rosenau, J2
Böker, KH1
Barg-Hock, H1
Becker, T1
Klempnauer, J2
Flemming, P1
Schernick, A1
Hopf, U1
Sevastianos, V1
Burroughs, AK1
Castelnau, C1
Boyer, N2
Klein, C1
Wüstefeld, T1
Dienes, HP1
Kubicka, S1
Vere Hodge, A1
Maier, KP1
Sablon, E2
Shapiro, F1
Liu, CL2
Fan, ST2
Lo, CM2
Wei, WI1
Yong, BH1
Wong, J1
Buster, EH1
Schalm, SW1
Hochman, JA1
Balistreri, WF1
Ratziu, V1
Yuen, MF1
Perrillo, RP2
Werle, B1
Cinquin, K1
Maynard, M1
Trépo, C3
Mao, YM1
Zeng, MD1
Toniutto, P1
Fumo, E1
Caldato, M1
Apollonio, L1
Perin, A1
Pirisi, M1
Cheung, ST1
Ng, IO1
Inoue, H1
Tanabe, R1
Tanaka, E1
Cooksley, WG1
Cahour, A1
Bozdayi, AM1
Eyigun, CP1
Turkyilmaz, AR1
Avci, IY1
Pahsa, A1
Jacob, JR1
Korba, BE2
Cote, PJ1
Toshkov, I1
Delaney, WE3
Gerin, JL1
Tennant, BC1
Seki, S1
Yamane, T1
Hino, M1
Kolyvanos Naumann, U1
Käser, L1
Vetter, W1
Palmer, P1
Scieux, C1
Neff, GW3
O'brien, CB2
Nery, J2
Shire, N1
Montalbano, M2
Ruiz, P2
Nery, C2
Safdar, K2
De Medina, M1
Tzakis, AG2
Schiff, ER3
Madariaga, J1
Lau, DT2
Duncan, R1
Shire, NJ1
Muslu, H1
Madariaga, JR1
Fernández-Botello, A1
Holý, A1
Moreno, V1
Sigel, H1
Wai, CT3
Prabhakaran, K1
Wee, A1
Lee, YM1
Dan, YY2
Sutedja, DS1
Mak, K1
Isaac, J1
Lee, KH1
Lee, HL1
Da Costa, M1
Lim, SG2
Hosaka, T1
Suzuki, F3
Suzuki, Y1
Saitoh, S1
Kobayashi, M1
Someya, T1
Sezaki, H1
Akuta, N1
Tsubota, A1
Arase, Y1
Ikeda, K1
Kumada, H3
Schewe, CK1
Vogel, M1
Däumer, M1
Weitner, L1
Matz, B1
Rockstroh, JK1
Akay, S1
Karasu, Z2
Akyildiz, M2
Tokat, Y1
Pérez-Roldán, F1
González-Carro, P1
Villafáñez-García, MC1
Garcia, A1
Mazuecos, A1
González, P1
Diaz, F1
Garcia, T1
Ceballos, M1
Rivero, M1
Herreros de Tejada Echanojáuregui, A1
Moreno Planas, JM1
Rubio González, E1
Portero Azorin, F1
López Monclús, J1
Revilla Negro, J1
Lucena de la Poza, JL1
Sánchez Turrión, V1
Barrios Peinado, C1
Cuervas-Mons Martínez, V1
Taltavull, TC1
Chahri, N1
Verdura, B1
Gornals, J1
Lopez, C1
Casanova, A1
Cañas, C1
Figueras, J1
Casais, LA1
Gelinck, LB1
Claas, EC1
Moon, W1
Choi, MS1
Moon, YM1
Koh, KC1
Yoo, BC1
Rhee, JC1
Shim, SG1
Esteban, R1
Li, HQ1
Li, JH1
Dong, JQ1
Gao, JR1
Gou, CY1
Fung, SK1
Han, SH1
Rajender Reddy, K1
Regev, A1
Keeffe, EB1
Richtmyer, P1
Marrero, JA1
Camino, N1
Rodés, B1
Kuiper, M1
Lutz, T1
Klausen, G1
Kim, KM1
Choi, WB1
Lee, HC1
Chung, YH1
Lee, YS1
Chowdhury, A1
Santra, A1
Chakravorty, R1
Banerji, A1
Pal, S1
Dhali, GK1
Datta, S1
Banerji, S1
Manna, B1
Chowdhury, SR1
Bhattacharya, SK1
Mazumder, DG1
Cortelezzi, A1
Zilioli, VR1
Fantini, NN1
Pasquini, MC1
Deliliers, GL1
Colombo, M4
Manenti, E2
Iavarone, M2
Lunghi, G1
Bárcena, R1
Del Campo, S1
Moraleda, G1
Casanovas, T1
Prieto, M1
Moreno, JM1
Cuervas, V1
Fraga, E1
De la Mata, M1
Otero, A1
Delgado, M1
Loinaz, C1
Barrios, C1
Dieguez, ML1
Sousa, JM1
Herrero, JI1
Muñoz, R1
Avilés, JF1
Gonzalez, A1
Rueda, M1
Shah, SR1
Osterhaus, AD1
Fouillard, L1
Fleury, H1
Trimoulet, P1
Pellegrin, I1
Urbinelli, R1
Rozenbaum, W1
Le Teuff, G1
Trylesinski, A1
Piketty, C1
Erion, MD1
Bullough, DA1
Lin, CC1
Hong, Z1
Schreibman, IR1
Yeoh, KG1
Núñez-Rodríguez, MH1
Santamaría-Martínez, A1
Mata-Román, L1
Caro-Patón, A1
Nakamura, H1
Pham, PA1
Gallant, JE1
Wong, SN3
Zöllner, B2
Hollinger, FB1
Dumortier, J1
Le Derf, Y1
Guillem, P1
Chevallier, P1
Boillot, O1
Levy, V1
Grant, RM1
Bouhassoune, K1
Calboreanu, A1
Alloui, C1
Rico-Garcia, M1
Salmon-Céron, D1
Legal, F1
Dény, P1
Sogni, P1
Podevin, P1
Helm, M1
Gerlich, W1
de Silva, HJ1
Dassanayake, AS1
Manamperi, A1
de Silva, AP1
Cakir, N1
Pamuk, ON1
Umit, H1
Midilli, K1
Parekh, NK1
Hester, J1
Lee, WM2
Kim, HJ1
Suh, JH1
Kim, DH1
Cho, YS1
Won, SY1
Park, BK1
Park, IS1
Aubourg, A1
d'Alteroche, L1
Senecal, D1
Gaudy, C1
Bacq, Y1
Comanor, L1
White, C1
Kipnis, P1
Elkin, C1
Leung, K1
Ocampo, A1
Attar, N1
Keiser, P1
Chu, CJ1
Howell, T1
Moore, C1
Hadziyannis, S1
Neuhaus, P1
Terrault, N1
Tillmann, H1
Villeneuve, JP1
Arterburn, S2
Brosgart, C2
Chuck, S1
Kemmer, N1
Kaiser, TE1
Zacharias, VC1
Alonzo, M1
Thomas, M1
Buell, J1
Rouphael, NG1
Talati, NJ1
Rimland, D1
Iino, S1
Yotsuyanagi, H2
Koike, K2
Moriconi, F1
Colombatto, P1
Coco, B1
Ciccorossi, P1
Oliveri, F1
Flichman, D1
Maina, AM1
Sacco, R1
Bonino, F1
Brunetto, MR1
Qi, X1
Xiong, S1
Yang, H1
Miller, M1
Painter, GR1
Almond, MR1
Trost, LC1
Lampert, BM1
Neyts, J1
Aldern, KA1
Beadle, JR1
Hostetler, KY1
Del Poggio, P1
Zaccanelli, M1
Oggionni, M1
Colombo, S1
Jamoletti, C1
Puhalo, V1
Nebbia, G1
Garcia-Diaz, A1
Ayliffe, U1
Smith, C1
Dervisevic, S1
Johnson, M1
Tedder, R1
Geretti, AM1
Cai, CJ1
Lu, MQ1
Jiang, N1
Wang, GS1
Yi, SH1
Zhang, JF1
Yi, HM1
Zhang, YC1
Chen, GH1
Niederau, C1
Yatsuji, H1
Hiraga, N1
Mori, N1
Hatakeyama, T1
Tsuge, M1
Imamura, M1
Takahashi, S2
Fujimoto, Y1
Abe, H1
Maekawa, T1
Chayama, K2
Yilmaz, N1
Todd Stravitz, R1
Maluf, D1
Coterell, A1
Zeytunlu, M1
Aydin, U1
Ozacar, T1
Kilic, M1
Husain, M1
Chen, JJ1
Ma, SW1
Wang, ZH1
Hou, JL1
Sung, JJ1
Lai, JY1
Chow, WC1
Heathcote, EJ1
Brosgart, CL1
Woessner, MA1
Scott, SA1
Gray, DF1
Gardner, SD1
Villet, S1
Pichoud, C1
Billioud, G1
Barraud, L1
Durantel, S1
Pellicelli, AM1
Barbaro, G1
Francavilla, R1
Romano, M1
Barbarini, G1
Mazzoni, E1
Mecenate, F1
Paffetti, A1
Barlattani, A1
Struglia, C1
Villani, R1
Nauri, L1
Nosotti, L1
Ferri, F1
Camporiondo, MP1
Soccorsi, F1
Hooman, N1
Rifai, K1
Hadem, J1
Vaske, B1
Philipp, G1
Priess, A1
Volzt, T1
Quaas, A1
Zankel, M1
Fischer, C1
Weber, A1
Carbonnel, F1
Simon, N1
Kantelip, B1
Coaquette, A1
Mantion, G1
Miguet, JP1
Di Martino, V1
Faria, LC1
Gigou, M1
Roque-Afonso, AM1
Sebagh, M1
Fallot, G1
Ferrari, TC1
Guettier, C1
Dussaix, E1
Castaing, D1
Brechot, C1
Freshwater, DA1
Dudley, T1
Cane, P1
Mutimer, DJ1
Bottecchia, M1
Madejón, A1
Van Bambeke, F1
Girke, J1
Laskus, T1
Persing, DH1
Nowicki, MJ1
Mosley, JW1
Rakela, J1
Kreuzfelder, E2
Menne, S2
Ferencik, S1
Roggendorf, M2
Grosse-Wilde, H2
Günther, S1
Sommer, G1
Plikat, U1
Iwanska, A1
Wain-Hobson, S1
Will, H1
Meyerhans, A1
Maschke, J1
Tolle, T1
Kajino, K1
Kamiya, N1
Yuasa, S1
Takahara, T1
Sakurai, J1
Yamamura, Ki1
Hino, O1
Pontisso, P1
Belluco, C1
Bertorelle, R1
De Moliner, L1
Chieco-Bianchi, L1
Nitti, D1
Lise, M1
Alberti, A1
Singer, G1
Howard, T1
Jacobsmeyer, S1
Gibbs, CS2
Lamy, P1
Murray, A1
de Vrueh, RL1
Rump, ET1
van De Bilt, E1
van Veghel, R1
Balzarini, J1
Biessen, EA1
van Berkel, TJ1
Bijsterbosch, MK1
Warner, D1
Hatse, S1
Suárez García, E1
Romero Gómez, M1
Grande Santamaría, L1
James, JS1
Highleyman, L1
Shaw, T1
Bochet, M1
Calvez, V1
Fievet, MH1
Vig, P1
Fry, J1
Namini, H1
Cullen, JM1
Li, DH1
Brown, C1
Eisenberg, EJ1
Cundy, KC1
Wolfe, J1
Toole, J1
Gibbs, C2
Delmas, J1
Schorr, O1
Jamard, C1
Hantz, O1
Sponseller, CA1
Ramrakhiani, S1
Castelneau, C1
Julander, JG1
Sidwell, RW1

Clinical Trials (22)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Cohort Study to Assess the Safety and Efficacy of Replacing Tenofovir Disoproxil Fumarate by Tenofovir Alafenamide in HIV/HBV-coinfected Patients With Mild or Moderate Renal Dysfunction[NCT03115736]Phase 224 participants (Actual)Interventional2017-05-23Completed
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 96w Open-label Multicenter Study[NCT04939441]Phase 4100 participants (Anticipated)Interventional2021-04-20Active, not recruiting
Efficacy and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients With Suboptimal Response Following Nucleos(t)Ide Therapy[NCT04201808]Phase 4100 participants (Anticipated)Interventional2021-05-01Recruiting
A Real-world Study of Optimizing Nucleotide-analogues-based Treatment for Chronic Hepatitis B[NCT05937178]20,000 participants (Anticipated)Observational2023-01-31Recruiting
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B[NCT01940341]Phase 3426 participants (Actual)Interventional2013-09-12Completed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B[NCT01940471]Phase 3875 participants (Actual)Interventional2013-09-11Completed
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study[NCT02344680]303 participants (Actual)Observational2015-10-31Active, not recruiting
Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy[NCT02995005]Phase 1/Phase 298 participants (Actual)Interventional2018-05-24Completed
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994]275 participants (Actual)Observational [Patient Registry]2018-02-06Active, not recruiting
Virological and Clinical Anti-HBV Efficacy of Tenofovir in Antiretroviral naïve Patients With HIV/HBV Co-infection[NCT00192595]Phase 436 participants (Actual)Interventional2004-01-31Completed
[NCT01139203]300 participants (Anticipated)Interventional2009-08-31Recruiting
[NCT02019966]1,020 participants (Actual)Observational2014-05-12Completed
A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated With Adef[NCT00307489]Phase 2106 participants (Actual)Interventional2006-03-31Completed
Comparative Study of the Effect of Entecavir Versus Tenofovir on the Presence of HBV DNA in the Peripheral Blood Mononuclear Cells in Chronic Hepatitis B Patients[NCT05168293]100 participants (Anticipated)Observational2022-02-01Not yet recruiting
Efficacy of HBV Therapeutic Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy: a Pilot Study[NCT02505009]Phase 4116 participants (Actual)Interventional2015-05-01Completed
Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection[NCT00662545]Phase 410 participants (Actual)Interventional2008-04-30Completed
A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks[NCT02474316]Phase 4366 participants (Anticipated)Interventional2014-08-31Recruiting
Safety and Efficacy of Tenofovir Alafenamide for Chronic Hepatitis B Patients With Decompensated Liver Disease[NCT04683341]Phase 4100 participants (Anticipated)Interventional2020-09-01Recruiting
Efficacy of Adefovir and Lamivudine Combination Therapy in Patients With Entecavir Resistance[NCT01546116]Phase 420 participants (Actual)Interventional2010-02-28Completed
A Randomized, Phase II, Controlled Trial Comparing the Efficacy of Adefovir Dipivoxil and Tenofovir Disoproxil Fumarate for the Treatment of Lamivudine-Resistant Hepatitis B Virus in Subjects Who Are Co-Infected With HIV[NCT00033163]Phase 290 participants InterventionalCompleted
A Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options[NCT00042393]0 participants Expanded AccessApproved for marketing
A Phase II Study of Adefovir Dipivoxil, Pegylated Interferon Alfa-2A, and Ribavirin Treatment in HBV and HCV Infected Subjects With HIV Disease[NCT00051077]Phase 20 participants (Actual)InterventionalWithdrawn
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Serum Creatinine at Week 48

(NCT01940341)
Timeframe: Baseline, Week 48

Interventionmg/dL (Mean)
TAF 25 mg0.01
TDF 300 mg0.02

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

(NCT01940341)
Timeframe: Baseline, Week 48

Interventionpercentage change (Mean)
TAF 25 mg-0.288
TDF 300 mg-2.156

Percent Change From Baseline in Spine BMD at Week 48

(NCT01940341)
Timeframe: Baseline, Week 48

Interventionpercentage change (Mean)
TAF 25 mg-0.876
TDF 300 mg-2.514

Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL

The primary efficacy endpoint was determined by the achievement of HBV DNA < 29 IU/mL at Week 48. (NCT01940341)
Timeframe: Week 48

InterventionPercentage of participants (Number)
TAF 25 mg94.0
TDF 300 mg92.9

Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. (NCT01940341)
Timeframe: Up to 48 weeks

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
TAF 25 mg18.11.10
TDF 300 mg16.42.10

Change From Baseline at Week 48 in Serum Creatinine

(NCT01940471)
Timeframe: Baseline, Week 48

Interventionmg/dL (Mean)
TAF 25 mg0.009
TDF 300 mg0.026

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

(NCT01940471)
Timeframe: Baseline, Week 48

Interventionpercentage change (Mean)
TAF 25 mg-0.100
TDF 300 mg-1.715

Percent Change From Baseline in Spine BMD at Week 48

(NCT01940471)
Timeframe: Baseline, Week 48

Interventionpercentage change (Mean)
TAF 25 mg-0.417
TDF 300 mg-2.294

Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion to Antibody Against Hepatitis B e Antigen (Anti-HBe) at Week 48

(NCT01940471)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg10.3
TDF 300 mg8.1

Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48

(NCT01940471)
Timeframe: Week 48

Interventionpercentage of participants (Number)
TAF 25 mg63.9
TDF 300 mg66.8

Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. (NCT01940471)
Timeframe: Up to 48 weeks

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
TAF 25 mg23.93.50
TDF 300 mg17.84.50.3

Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168

(NCT00307489)
Timeframe: 168 weeks

InterventionU/mL (Mean)
Tenofovir DF-26.8
Emtricitibine/Tenofovir DF-54.5

Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48

(NCT00307489)
Timeframe: 48 Weeks

InterventionU/mL (Mean)
Tenofovir DF-21.6
Emtricitibine/Tenofovir DF-41.4

Change From Baseline in log10 Plasma HBV DNA Levels at Week 168

(NCT00307489)
Timeframe: 168 weeks

Interventionlog10 copies/mL (Mean)
Tenofovir DF-3.79
Emtricitibine/Tenofovir DF-3.48

Change From Baseline in log10 Plasma HBV DNA Levels at Week 48

(NCT00307489)
Timeframe: 48 Weeks

Interventionlog10 copies/mL (Mean)
Tenofovir DF-3.58
Emtricitibine/Tenofovir DF-3.34

HBeAg Seroconversion at Week 48

Defined as having negative serum HBeAg and positive serum antibody to HBeAg [anti-HBe] for subjects with positive serum HBeAg at baseline. (NCT00307489)
Timeframe: 48 Weeks

Interventionparticipants (Number)
Tenofovir DF2
Emtricitibine/Tenofovir DF3

HBsAg Loss at Week 168

Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline. (NCT00307489)
Timeframe: 168 weeks

InterventionParticipants (Number)
Tenofovir DF1
Emtricitibine/Tenofovir DF0

HBsAg Loss at Week 48

Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline. (NCT00307489)
Timeframe: 48 Weeks

Interventionparticipants (Number)
Tenofovir DF1
Emtricitibine/Tenofovir DF0

Hepatitis B Early Antigen (HBeAg) Loss at Week 168

Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline. (NCT00307489)
Timeframe: 168 weeks

InterventionPercent of Participants (Number)
Tenofovir DF21.6
Emtricitibine/Tenofovir DF24.3

Hepatitis B Early Antigen (HBeAg) Loss at Week 48

Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline. (NCT00307489)
Timeframe: 48 Weeks

Interventionparticipants (Number)
Tenofovir DF3
Emtricitibine/Tenofovir DF3

Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168

Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline. (NCT00307489)
Timeframe: 168 weeks

InterventionParticipants (Number)
Tenofovir DF1
Emtricitibine/Tenofovir DF0

Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48

Defined as having negative serum HBsAg and positive serum antibody to HBsAg [anti-HBs] for subject with positive serum HBsAg at baseline. (NCT00307489)
Timeframe: 48 Weeks

Interventionparticipants (Number)
Tenofovir DF1
Emtricitibine/Tenofovir DF0

Percentage of Participants With Normal ALT at Week 168

ULN for males = 43 U/L; ULN for females = 34 U/L (NCT00307489)
Timeframe: 168 weeks

InterventionPercent of Participants (Number)
Tenofovir DF74.0
Emtricitibine/Tenofovir DF74.0

Percentage of Participants With Normal ALT at Week 48

ULN for males = 43 U/L; 34 U/L for females (NCT00307489)
Timeframe: 48 Weeks

Interventionpercentage of participants (Number)
Tenofovir DF66.7
Emtricitibine/Tenofovir DF73.1

Percentage of Participants With Normalized ALT at Week 168

Subjects with elevated ALT at baseline that return to normal by Week 48. (NCT00307489)
Timeframe: 168 weeks

InterventionPercent of Participants (Number)
Tenofovir DF68.0
Emtricitibine/Tenofovir DF70.8

Percentage of Participants With Normalized ALT at Week 48

Subjects with elevated ALT at baseline that return to normal by Week 48. (NCT00307489)
Timeframe: 48 Weeks

Interventionpercentage of participants (Number)
Tenofovir DF40.7
Emtricitibine/Tenofovir DF61.5

Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168

P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use. (NCT00307489)
Timeframe: 168 weeks

InterventionPercent of Participants (Number)
Tenofovir DF80.4
Emtricitibine/Tenofovir DF78.0

Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48

(NCT00307489)
Timeframe: 48 weeks

Interventionpercentage of participants (Number)
Tenofovir DF75.5
Emtricitibine/Tenofovir DF69.2

Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168

(NCT00307489)
Timeframe: 168 weeks

InterventionPercent of Participants (Number)
Tenofovir DF82.4
Emtricitibine/Tenofovir DF84.0

Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48

(NCT00307489)
Timeframe: 48 Weeks

Interventionpercentage of participants (Number)
Tenofovir DF81.1
Emtricitibine/Tenofovir DF80.8

Hepatitis B Virus (HBV) DNA

"HBV DNA carries the genetic blueprint of the virus. How many HBV DNA particles or copies are found in the blood indicates how rapidly the virus is reproducing in the liver." (NCT00662545)
Timeframe: week 24

Interventionlog 10 IU/ml (Median)
Entecavir Intensification2.4
Standard of Care0.8

HIV RNA < 75 Copies/ml

(NCT00662545)
Timeframe: entry, week 12, and week 24

Interventionparticipants (Number)
Entecavir Intensification5
Standard of Care5

Incidence of ALT Flares

ALT flare: sudden increase in blood level of alanine transaminase (ALT) (NCT00662545)
Timeframe: every 4 weeks for 24 weeks

Interventionparticipants (Number)
Entecavir Intensification0
Standard of Care0

Incidence of New Hepatic Decompensation( Ascites, Variceal Hemorrhage, Encephalopathy)

(NCT00662545)
Timeframe: every 4 weeks for 24 weeks

Interventionparticipants (Number)
Entecavir Intensification0
Standard of Care0

Incidence of Permanent Discontinuation Due to Toxicity

(NCT00662545)
Timeframe: 24 weeks

Interventionparticipants (Number)
Entecavir Intensification0
Standard of Care0

Reviews

78 reviews available for adenine and Hepatitis B

ArticleYear
Adefovir for lamivudine-resistant hepatitis B.
    Antiviral therapy, 2022, Volume: 27, Issue:2

    Topics: Adenine; Drug Resistance, Viral; Hepatitis B; Humans; Lamivudine; Organophosphonates

2022
The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B.
    Journal of clinical gastroenterology, 2023, 02-01, Volume: 57, Issue:2

    Topics: Adenine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infectious Dis

2023
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
    Hepatology international, 2023, Volume: 17, Issue:4

    Topics: Adenine; Alanine; Cholesterol; Cholesterol, LDL; Dyslipidemias; Hepatitis B; Hepatitis B, Chronic; H

2023
Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
    BMC gastroenterology, 2023, Nov-10, Volume: 23, Issue:1

    Topics: Adenine; Alanine; Antiviral Agents; Bone and Bones; Creatinine; Fumarates; Hepatitis B; Hepatitis B,

2023
[Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023, Oct-20, Volume: 31, Issue:10

    Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans;

2023
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.
    International journal of molecular sciences, 2021, Feb-01, Volume: 22, Issue:3

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Genotype; Guanine; Hepatitis B; He

2021
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.
    Biochemical pharmacology, 2018, Volume: 153

    Topics: Adenine; Alanine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B;

2018
Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.
    Current opinion in nephrology and hypertension, 2018, Volume: 27, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Drug Interactions; Glomerular Filtration Rate; Hep

2018
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
    BMC infectious diseases, 2018, Nov-14, Volume: 18, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B

2018
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adenine; Anti-HIV Agents; Coinfection; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Organ

2013
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Adenine; Administration, Oral; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Guanine; Hepat

2014
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:10

    Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus;

2014
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
    Expert opinion on biological therapy, 2014, Volume: 14, Issue:7

    Topics: Adenine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-

2014
Liquid oral suspension adefovir dipivoxil (GS-02-526): an update on treatments for hepatitis B infection.
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:8

    Topics: Adenine; Administration, Oral; Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Dose-Response

2014
Prevention of hepatitis B virus reinfection in liver transplant recipients.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobulins; Liver;

2014
Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jan-15, Volume: 60, Issue:2

    Topics: Adenine; Anti-HIV Agents; Breast Feeding; Disease Transmission, Infectious; Female; Hepatitis B; Hum

2015
Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
    Oncotarget, 2016, May-24, Volume: 7, Issue:21

    Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hepa

2016
Tenofovir alafenamide (Vemlidy) for hepatitis B.
    The Medical letter on drugs and therapeutics, 2017, Jan-02, Volume: 59, Issue:1511

    Topics: Adenine; Alanine; Animals; Antiviral Agents; Clinical Trials as Topic; Hepatitis B; Humans; Tenofovi

2017
Hepatitis B and liver transplantation: 2008 update.
    Reviews in medical virology, 2009, Volume: 19, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B Vaccines; Hu

2009
[Interferon in hepatitis B].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 7

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Guanine; H

2008
[Hepatitis B in patients with HIV infection].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 7

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deox

2008
Hepatitis B therapy in children.
    Expert review of gastroenterology & hepatology, 2009, Volume: 3, Issue:1

    Topics: Adenine; Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepatitis

2009
Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
    Current opinion in organ transplantation, 2009, Volume: 14, Issue:3

    Topics: Adenine; Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combina

2009
The option of liver transplantation for hepatitis B: where are we?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2009, Volume: 41 Suppl 2

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B; Humans; Immunoglobulins; Lamivudi

2009
Liver transplantation for hepatitis B virus. Pre-emptive and peri-operative prophylaxis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2009, Volume: 41 Suppl 2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Hepa

2009
Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis.
    Transplant infectious disease : an official journal of the Transplantation Society, 2010, Aug-01, Volume: 12, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Controlled Clinical Trials as Topic; Drug Therapy,

2010
Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.
    World journal of gastroenterology, 2010, May-28, Volume: 16, Issue:20

    Topics: Adenine; Antiviral Agents; Asia; Guanine; Hepatitis B; Hepatitis B virus; Humans; Interferons; Lamiv

2010
Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation.
    The Cochrane database of systematic reviews, 2010, Jul-07, Issue:7

    Topics: Adenine; Antiviral Agents; Hepatitis B; Humans; Immunoglobulins; Lamivudine; Liver Transplantation;

2010
Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature.
    Journal of Crohn's & colitis, 2010, Volume: 4, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Colitis, Ulcerative; Crohn Disease; Drug Therapy

2010
The impact of human immunodeficiency virus on viral hepatitis.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitab

2011
The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond.
    Biochemical pharmacology, 2011, Jul-15, Volume: 82, Issue:2

    Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Cidofovir; Cytosine; Guanosine; Hepatitis B; HIV I

2011
Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2011, Volume: 17, Issue:10

    Topics: Adenine; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Evidence-Based Medici

2011
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
    Antiviral therapy, 2011, Volume: 16, Issue:5

    Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatiti

2011
Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:4

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Humans; Interferons; Lamivudine; Liver Failure, Acu

2012
[Pharmacological treatment of acute hepatitis B].
    Medicina clinica, 2012, May-19, Volume: 138, Issue:14

    Topics: Acute Disease; Adenine; Antiviral Agents; Guanine; Hepatitis B; Humans; Lamivudine; Nucleosides; Org

2012
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:6

    Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combin

2012
Update on tenofovir toxicity in the kidney.
    Pediatric nephrology (Berlin, Germany), 2013, Volume: 28, Issue:7

    Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Hepatitis B; HIV Infections; Humans; Kidney; Ki

2013
High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2013, Volume: 13, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobul

2013
Prevention of recurrent hepatitis B post-liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2002, Volume: 8, Issue:10 Suppl 1

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Humans; Immunoglobulins; Lamivudine; Liver Transpla

2002
Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Clinical therapeutics, 2002, Volume: 24, Issue:10

    Topics: Adenine; Animals; Anti-HIV Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug

2002
Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2003, Volume: 3, Issue:3

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Transp

2003
Management of patients with decompensated HBV cirrhosis.
    Seminars in liver disease, 2003, Volume: 23, Issue:1

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance; Hepatiti

2003
[Treatment of hepatitis B].
    La Revue de medecine interne, 2002, Volume: 23 Suppl 5

    Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis

2002
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
    Praxis, 2003, Aug-13, Volume: 92, Issue:33

    Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B S

2003
Early detection of hepatitis B drug resistance: implications for patient management.
    Expert review of molecular diagnostics, 2003, Volume: 3, Issue:5

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B; Hepatitis B vi

2003
Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions.
    Antiviral research, 2003, Volume: 60, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B vir

2003
Chronic viral hepatitis: always be current!
    Pediatrics in review, 2003, Volume: 24, Issue:12

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis B; Hepatitis B v

2003
Viral hepatitis B.
    Lancet (London, England), 2003, Dec-20, Volume: 362, Issue:9401

    Topics: Adenine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepatitis B; Hepatitis

2003
Management of the patient with hepatitis B virus-related cirrhosis.
    Journal of hepatology, 2003, Volume: 39 Suppl 1

    Topics: Adenine; Antiviral Agents; Hepatitis B; Humans; Interferons; Lamivudine; Liver Cirrhosis; Nucleoside

2003
[Adefovir dipivoxil-A new drug for hepatitis B].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2004, Volume: 12, Issue:1

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B; Humans; Organophosphonates

2004
Molecular virology of hepatitis B virus.
    Seminars in liver disease, 2004, Volume: 24 Suppl 1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B; Hepat

2004
Hepatitis B virus kinetics and mathematical modeling.
    Seminars in liver disease, 2004, Volume: 24 Suppl 1

    Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatocytes; Lamivudine; Mode

2004
The role of interferon therapy in hepatitis B.
    MedGenMed : Medscape general medicine, 2004, Mar-18, Volume: 6, Issue:1

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B; Humans; Interferon-alpha; Lamivudi

2004
Current antiviral therapy for chronic hepatitis B.
    Journal of Korean medical science, 2004, Volume: 19, Issue:4

    Topics: Adenine; Antiviral Agents; Hepatitis B; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Re

2004
[Hepatitis B (acute and chronic)].
    Praxis, 2004, Jul-28, Volume: 93, Issue:31-32

    Topics: Acute Disease; Adenine; Adolescent; Adult; Antiviral Agents; Child; Diagnosis, Differential; Drug Th

2004
Adefovir-lamivudine combination therapy and hepatitis B viral kinetics.
    Journal of hepatology, 2005, Volume: 43, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B; Hepatitis B e Antigens; Hepatitis

2005
Drugs in development for hepatitis B.
    Drugs, 2005, Volume: 65, Issue:11

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Guanine; Hepatitis

2005
Understanding hepatitis B.
    The Journal of the Association of Physicians of India, 2005, Volume: 53

    Topics: Acute Disease; Adenine; Algorithms; Antiviral Agents; Hepatitis B; Humans; Interferon alpha-2; Inter

2005
HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver.
    Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:2

    Topics: Adenine; Animals; Antiviral Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Del

2006
Hepatitis B virus genotypes and response to antiviral therapy.
    Clinical laboratory, 2006, Volume: 52, Issue:1-2

    Topics: Adenine; Antiviral Agents; Genotype; Hepatitis B; Hepatitis B virus; Humans; Interferon-alpha; Lamiv

2006
Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues.
    Annals of clinical microbiology and antimicrobials, 2006, Apr-06, Volume: 5

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Humans; Immunoglobulins;

2006
Tenofovir disoproxil fumarate for the treatment of HIV infection.
    Expert opinion on drug metabolism & toxicology, 2006, Volume: 2, Issue:3

    Topics: Adenine; Animals; Drug Administration Schedule; Drug Interactions; Drug Resistance, Viral; Drug Ther

2006
Tenofovir disoproxil fumarate: role in hepatitis B treatment.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:2

    Topics: Adenine; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Organophosphonates; Tenofovir; Treatmen

2006
Hepatitis B: the pathway to recovery through treatment.
    Gastroenterology clinics of North America, 2006, Volume: 35, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B; Hepatitis C, Chronic; Human

2006
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Oct-01, Volume: 43, Issue:7

    Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Combinations;

2006
[Therapy of hepatitis B virus infection].
    Praxis, 2006, Sep-06, Volume: 95, Issue:36

    Topics: Adenine; Antiviral Agents; Drug Antagonism; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Co

2006
[Managing lamivudine resistance in liver transplantation for hepatitis B liver disease].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:10 Pt 2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis

2006
[Impact of resistance to analogue antivirals and therapeutic strategies in situations of dialysis, kidney transplantation, vasculitis, and preemptive treatments in immunosuppressed patients].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:10 Pt 2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis

2006
Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature.
    AIDS (London, England), 2007, Mar-30, Volume: 21, Issue:6

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; CD4 Lymphocyte Count; DNA, Viral; Hepatiti

2007
[Drugs for hepatitis B and C infection].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Feb-28, Volume: 65 Suppl 2 Pt. 1

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepat

2007
[Mechanisms of drug resistance in hepatitis viruses B and C].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Feb-28, Volume: 65 Suppl 2 Pt. 1

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Guanine; Hepacivirus; Hepatit

2007
Drug resistance in antiviral treatment for infections with hepatitis B and C viruses.
    Journal of gastroenterology, 2007, Volume: 42, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepacivirus; Hepatitis B; Hepatitis B vi

2007
[Attention-getting sexually transmitted diseases: Hepatitis B].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Nov-10, Volume: 96, Issue:11

    Topics: Adenine; Adenosine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Guanine; Gua

2007
[The ABC of viral hepatitis].
    Journal de pharmacie de Belgique, 2008, Volume: 63, Issue:1

    Topics: Adenine; Antiviral Agents; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis, Viral, Human; Humans; I

2008
Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
    Antiviral chemistry & chemotherapy, 2001, Volume: 12, Issue:1

    Topics: 2-Aminopurine; Adenine; Amino Acid Sequence; Animals; Anti-HIV Agents; Antimetabolites; Antiviral Ag

2001
Treatment of hepatitis B and C following liver transplantation.
    Current gastroenterology reports, 2002, Volume: 4, Issue:1

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Resistance; Drug Ther

2002
[New management strategies for hepatitis B].
    Gastroenterologie clinique et biologique, 2002, Volume: 26, Issue:2

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Guanine; Hepatitis

2002

Trials

43 trials available for adenine and Hepatitis B

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Risk of hepatitis B virus reactivation in patients treated with ibrutinib.
    Blood, 2018, 04-26, Volume: 131, Issue:17

    Topics: Adenine; Aged; Aged, 80 and over; Female; Follow-Up Studies; Hematologic Neoplasms; Hepatitis B; Hep

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN

2018
Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; Disease-Free Survival; DNA, Viral; Drug Therapy,

2013
Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis.
    World journal of gastroenterology, 2013, Jun-14, Volume: 19, Issue:22

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Chi-Square Distribution; China;

2013
Impact on L-carnitine Homeostasis of Short-term Treatment with the Pivalate Prodrug Tenofovir Dipivoxil.
    Basic & clinical pharmacology & toxicology, 2013, Volume: 113, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; Carnitine; Dose-Response Relationship, Drug; Female; Hepatitis B;

2013
De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.
    World journal of gastroenterology, 2013, Oct-07, Volume: 19, Issue:37

    Topics: Adenine; Adult; Alanine Transaminase; Analysis of Variance; Antiviral Agents; Biomarkers; Chi-Square

2013
Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:10

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination;

2014
Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women.
    Digestive diseases and sciences, 2014, Volume: 59, Issue:11

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Humans; Infant, Newbo

2014
Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
    Annals of surgery, 2015, Volume: 261, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis

2015
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
    Journal of acquired immune deficiency syndromes (1999), 2016, 11-01, Volume: 73, Issue:3

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Em

2016
[Adefovir dipivoxil treatment of hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2008, Volume: 16, Issue:5

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Female; Glomerulonephritis; Hepatitis B; Hepatitis B v

2008
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Antiviral therapy, 2008, Volume: 13, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA Mutational Analysis; DNA

2008
[Lamivudine and adefovir dipivoxil combination treatment for liver cirrhosis patients with CHB].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2008, Volume: 16, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B;

2008
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:4

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclo

2008
Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.
    Antiviral therapy, 2008, Volume: 13, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepati

2008
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Humans; Immunization, Passi

2008
Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
    Antiviral therapy, 2008, Volume: 13, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatit

2008
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; DNA, Viral; Drug The

2009
Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:8

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Fe

2009
Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:1

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistanc

2010
Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:10

    Topics: Adenine; Adult; Age Factors; Aged; Creatine; Drug Resistance, Viral; Drug Therapy, Combination; Fema

2011
Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Antiviral therapy, 2012, Volume: 17, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Cloning, Molecular; DNA, Viral; Drug Administ

2012
Relative bioavailability study of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy male fasted volunteers.
    Clinical drug investigation, 2012, May-01, Volume: 32, Issue:5

    Topics: Adenine; Administration, Oral; Adolescent; Adult; Area Under Curve; Biological Availability; Cross-O

2012
Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2012, Volume: 18, Issue:7

    Topics: Adenine; Adult; Aged; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Humans

2012
Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:6

    Topics: Adenine; Adolescent; Adult; Aged; Aleutian Mink Disease Virus; Antiviral Agents; Drug Therapy, Combi

2012
Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:2

    Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female;

2013
Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:1

    Topics: Adenine; Alanine Transaminase; Amino Acid Sequence; Antigens, Viral; Antiviral Agents; Biopsy; DNA-D

2004
Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Oct-01, Volume: 39, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Hepatitis B; HIV Infections; Hum

2004
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
    Antiviral therapy, 2005, Volume: 10, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; H

2005
Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.
    Journal of Korean medical science, 2005, Volume: 20, Issue:5

    Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; Drug Combinations; Drug Resistance, V

2005
Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
    Journal of medical virology, 2006, Volume: 78, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Evolution, M

2006
Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Female

2007
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B;

2007
Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2007, Volume: 13, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B Surface Antigen

2007
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2007, Volume: 13, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2007
Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B.
    World journal of gastroenterology, 2007, Aug-14, Volume: 13, Issue:30

    Topics: Adenine; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Fe

2007
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
    Gastroenterology, 2007, Volume: 133, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; Dru

2007
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
    Journal of hepatology, 2008, Volume: 48, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther

2008
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
    Journal of hepatology, 2008, Volume: 48, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther

2008
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
    Journal of hepatology, 2008, Volume: 48, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther

2008
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
    Journal of hepatology, 2008, Volume: 48, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Ther

2008
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.
    Journal of hepatology, 2008, Volume: 48, Issue:5

    Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy,

2008
Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
    Antiviral therapy, 2008, Volume: 13, Issue:1

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Dr

2008
Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Gastroenterology, 2008, Volume: 134, Issue:7

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Circular; DNA, V

2008
Hepatitis B and adefovir depivoxil.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:2

    Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; Controlled Clinical Trials as Topi

1997

Other Studies

262 other studies available for adenine and Hepatitis B

ArticleYear
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:7

    Topics: Adenine; Alanine; Body Weight; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged;

2022
Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022, Volume: 20, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; China; Cleft Lip; Cleft Palate; Female; Hepatitis B; Hepatitis B S

2022
A nanofiber based antiviral (TAF) prodrug delivery system.
    Biomaterials advances, 2022, Volume: 133

    Topics: Adenine; Antiviral Agents; Hepatitis B; Humans; Nanofibers; Polymers; Prodrugs

2022
Case of psoriasis with hepatitis B virus infection during tumor necrosis factor inhibitor treatment successfully treated with ixekizumab and tenofovir alafenamide fumarate.
    The Journal of dermatology, 2022, Volume: 49, Issue:6

    Topics: Adenine; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Fumarates; Hepatitis B; Hepat

2022
DNA N6-Adenine methylation in HBV-related hepatocellular carcinoma.
    Gene, 2022, May-15, Volume: 822

    Topics: Adenine; Carcinoma, Hepatocellular; DNA Methylation; Epigenesis, Genetic; Genome-Wide Association St

2022
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:3

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections;

2022
Successful Treatment of Tenofovir Alafenamide-Induced Lactic Acidosis: A Case Report.
    Journal of pharmacy practice, 2023, Volume: 36, Issue:5

    Topics: Acidosis, Lactic; Adenine; Antiviral Agents; Hepatitis B; Humans; Male; Middle Aged; Tenofovir

2023
A carrier-free metal-organic hybrid nanoassembly with combination anti-viral and hepato-protective activity for hepatitis B treatment.
    Biomaterials science, 2022, Jul-26, Volume: 10, Issue:15

    Topics: Adenine; Animals; Antiviral Agents; DNA Replication; DNA, Viral; Hepatitis B; Hepatitis B virus; Inf

2022
Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed.
    Hepatology international, 2022, Volume: 16, Issue:4

    Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Hu

2022
Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:3

    Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Milk, Human;

2022
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2022, Volume: 42, Issue:11

    Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Long

2022
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
    Journal of medical virology, 2023, Volume: 95, Issue:2

    Topics: Adenine; Alanine; Antiviral Agents; Hepatitis A; Hepatitis B; Hepatitis B virus; Hepatitis B, Chroni

2023
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation.
    Annals of transplantation, 2023, Apr-21, Volume: 28

    Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Li

2023
The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma.
    Molecular medicine (Cambridge, Mass.), 2020, 06-17, Volume: 26, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Gene Express

2020
    The Journal of biological chemistry, 2020, 09-11, Volume: 295, Issue:37

    Topics: Adenine; DEAD Box Protein 58; Hep G2 Cells; Hepatitis B; Hepatitis C; Humans; Immune Evasion; Immuni

2020
Acceptance of antiviral treatment and enhanced service model for pregnant patients carrying hepatitis B.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2020, Volume: 26, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B Surface Antigens; Hep

2020
Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
    Journal of acquired immune deficiency syndromes (1999), 2020, 10-01, Volume: 85, Issue:2

    Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Female; Glomerular Filtration Rate; Hepatitis B; Hepatitis

2020
Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
    Journal of medicinal chemistry, 2020, 11-25, Volume: 63, Issue:22

    Topics: Adenine; Animals; Antiviral Agents; DNA, Circular; DNA, Viral; Drug Resistance, Viral; Guanine; Hepa

2020
Is HBV prophylaxis required during CLL treatment with ibrutinib?
    Leukemia & lymphoma, 2017, Volume: 58, Issue:12

    Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Biomarkers; Hepatitis B; Humans; Leukemia, Lymphoc

2017
Adefovir dipivoxil loaded proliposomal powders with improved hepatoprotective activity: formulation, optimization, pharmacokinetic, and biodistribution studies.
    Journal of liposome research, 2018, Volume: 28, Issue:4

    Topics: Adenine; Animals; Antiviral Agents; Biological Availability; Drug Carriers; Hepatitis B; Liposomes;

2018
Nephrolithiasis and Osteomalacia associated with adefovir-induced Fanconi syndrome in a patient with hepatitis B.
    BMC nephrology, 2017, Aug-29, Volume: 18, Issue:1

    Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B; Humans; Male; Middle Aged; Nephrolithiasis

2017
Adefovir-induced Fanconi syndrome associated with osteomalacia.
    Clinical and molecular hepatology, 2018, Volume: 24, Issue:3

    Topics: Adenine; Adult; Bone and Bones; Fanconi Syndrome; Female; Fibroblast Growth Factor-23; Fibroblast Gr

2018
Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Nov-02, Volume: 23

    Topics: Adenine; Adult; Alanine Transaminase; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B; H

2017
Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Adenine; Aged; Antiviral Agents; Fatal Outcome; Feasibility Studies; Female; Hepatitis B; Hepatitis

2018
Osteomalacia Due to Drug-Induced Fanconi Syndrome.
    Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:7

    Topics: Adenine; Aged; Antiviral Agents; Fanconi Syndrome; Hepatitis B; Humans; Male; Organophosphonates; Os

2018
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:5

    Topics: Acidosis, Lactic; Adenine; Aged; Alanine; Antiviral Agents; Fatal Outcome; Hematopoietic Stem Cell T

2018
Superior vena cava syndrome with concomitant upper extremity deep vein thrombosis.
    Internal and emergency medicine, 2019, Volume: 14, Issue:2

    Topics: Adenine; Aged; Female; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyr

2019
Very late onset post-transplant diffuse large B cell lymphoma in a liver transplant recipient with hepatitis B: A case report.
    Medicine, 2018, Volume: 97, Issue:44

    Topics: Adenine; Antiviral Agents; Biopsy, Fine-Needle; Chemoradiotherapy; Guanine; Hepatitis B; Hepatitis B

2018
Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:8

    Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Female; Hepatitis B; HIV Infections; Humans; Ma

2019
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:5

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; He

2019
Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2019, Volume: 29, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; China; Female; Guanine; Hepatitis

2019
Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report.
    Journal of medical case reports, 2019, Apr-20, Volume: 13, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Bone Density Conservation Agents; Denosumab; Fanconi Syndrome; Hep

2019
High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
    Journal of medical virology, 2013, Volume: 85, Issue:5

    Topics: Adenine; Antiviral Agents; Codon, Nonsense; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B;

2013
Hepatitis B therapy, hepatocellular carcinoma and HBsAg mutants.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:6

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Hepatit

2013
Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:12

    Topics: Adenine; Adult; Alanine Transaminase; Anti-Retroviral Agents; Antibiotic Prophylaxis; Drug Resistanc

2013
Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
    Transplantation proceedings, 2013, Volume: 45, Issue:2

    Topics: Adenine; Adult; Alanine Transaminase; Anemia, Aplastic; Antiviral Agents; Aspartate Aminotransferase

2013
Prevention of de novo hepatitis B with adefovir plus vaccination in recipients of liver transplants from core antibody-positive donors.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; Deoxycytidine; DNA, Viral; Drug Substitution; Em

2013
Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Transplantation, 2013, Apr-15, Volume: 95, Issue:7

    Topics: Adenine; Adult; Aged; Analysis of Variance; Antiviral Agents; Biomarkers; Chi-Square Distribution; D

2013
Tenofovir treatment of the severe acute hepatitis B.
    Revista espanola de enfermedades digestivas, 2013, Volume: 105, Issue:1

    Topics: Acute Disease; Adenine; Antiviral Agents; Hepatitis B; Humans; Male; Middle Aged; Organophosphonates

2013
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy.
    BMC research notes, 2013, Apr-17, Volume: 6

    Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Cross-Sectional Studies; Deoxycytidine; Emtrici

2013
Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation.
    Pharmacotherapy, 2013, Volume: 33, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; H

2013
Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:9

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance; Drug Therapy, Combi

2013
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.
    The Journal of infection, 2013, Volume: 67, Issue:4

    Topics: Adenine; Adult; Cell Line; Codon, Nonsense; Drug Resistance, Viral; Female; Gene Expression; Hepatit

2013
WHO survey finds half of countries do not have clinical guidelines for treating hepatitis.
    BMJ (Clinical research ed.), 2013, Jul-24, Volume: 347

    Topics: Adenine; Antiviral Agents; Drugs, Essential; Global Health; Guanine; Health Priorities; Hepatitis B;

2013
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
    Journal of acquired immune deficiency syndromes (1999), 2013, Oct-01, Volume: 64, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection;

2013
In vivo antiviral activity of telbivudine against HIV-1: a case report.
    Le infezioni in medicina, 2013, Volume: 21, Issue:3

    Topics: Acute Disease; Adenine; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B

2013
Analysis and simulation of an Adefovir anti-hepatitis B virus infection therapy immune model with alanine aminotransferase.
    IET systems biology, 2013, Volume: 7, Issue:5

    Topics: Adenine; Alanine Transaminase; Algorithms; Antiviral Agents; Computer Simulation; DNA, Viral; Hepati

2013
HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:7

    Topics: Adenine; Base Sequence; Cloning, Molecular; DNA Primers; Drug Resistance, Viral; Genotype; Hepatitis

2014
Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection.
    World journal of gastroenterology, 2013, Dec-28, Volume: 19, Issue:48

    Topics: Adenine; Antiviral Agents; Biomarkers; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepa

2013
Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014, Volume: 14, Issue:3

    Topics: Adenine; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Follow-Up Studies;

2014
Experimental and molecular docking studies on DNA binding interaction of adefovir dipivoxil: advances toward treatment of hepatitis B virus infections.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2014, May-05, Volume: 125

    Topics: Absorption; Adenine; Animals; Cattle; Circular Dichroism; DNA; Electrons; Hepatitis B; Hepatitis B v

2014
[Patient with HBsAg negativization during treatment. Could it be considered a cure for hepatitis B?].
    Gastroenterologia y hepatologia, 2014, Volume: 37, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Hepatitis B; Hepatitis B Surface Antigens; Humans; Male; Organopho

2014
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection;

2014
Clinical problem-solving. Wasting away.
    The New England journal of medicine, 2014, Mar-06, Volume: 370, Issue:10

    Topics: Adenine; Adult; Bone Diseases, Metabolic; Cachexia; Diagnosis, Differential; Fanconi Syndrome; Femal

2014
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
    Journal of acquired immune deficiency syndromes (1999), 2014, Jun-01, Volume: 66, Issue:2

    Topics: Adenine; Adult; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymp

2014
Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
    Antiviral therapy, 2014, Volume: 19, Issue:6

    Topics: Adenine; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Codon; DNA, Viral; Drug Resistance,

2014
Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.
    Journal of hepatology, 2014, Volume: 61, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Gastrointestinal Diseases; Hepatitis B; He

2014
Tenofovir disoproxil fumarate rescue therapy for HBV recurrence in two liver transplant recipients with previous multiple nucleo(s/t)ide treatment failures.
    Transplant international : official journal of the European Society for Organ Transplantation, 2014, Volume: 27, Issue:10

    Topics: Adenine; Aged; Follow-Up Studies; Graft Rejection; Graft Survival; Hepatitis B; Humans; Liver Failur

2014
Self-assembled drug delivery systems. Part 7: hepatocyte-targeted nanoassemblies of an adefovir lipid derivative with cytochrome P450-triggered drug release.
    International journal of pharmaceutics, 2014, Sep-10, Volume: 472, Issue:1-2

    Topics: Adenine; Animals; Antiviral Agents; Cytochrome P-450 Enzyme System; Drug Delivery Systems; Hepatitis

2014
An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:12

    Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Hepatitis

2014
HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy.
    World journal of gastroenterology, 2014, Jul-14, Volume: 20, Issue:26

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Therapy

2014
Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus.
    Clinical and molecular hepatology, 2014, Volume: 20, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female;

2014
The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center.
    European journal of internal medicine, 2014, Volume: 25, Issue:8

    Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Female;

2014
Peroxisome proliferator-activated receptor α activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway.
    Cell death & disease, 2014, Aug-28, Volume: 5

    Topics: Acute Disease; Adenine; Adult; Animals; Autophagy; Autophagy-Related Protein 7; Cells, Cultured; Che

2014
[Retrospective analysis of the efficacy and safety of anti-hepatitis B virus drugs taken during pregnancy in women from the Guangdong Province].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:7

    Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B; Hepatitis B virus; Humans; Infant; Infant,

2014
First report of successful clearance of hepatitis B and D coinfection with tenofovir monotherapy.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1

    Topics: Adenine; Adult; Coinfection; Hepatitis B; Hepatitis D; Humans; Male; Organophosphonates; Reverse Tra

2015
Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Antiviral research, 2014, Volume: 112

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B, Ch

2014
Editorial commentary: the conundrum of Lamivudine and tenofovir disoproxil fumarate for hepatitis B: fetus versus infant.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jan-15, Volume: 60, Issue:2

    Topics: Adenine; Anti-HIV Agents; Breast Feeding; Disease Transmission, Infectious; Female; Hepatitis B; Hum

2015
[Clinical pathology of recurrent hepatitis B after liver transplantation].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:9

    Topics: Adenine; Antiviral Agents; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hep

2014
Postexposure prophylactic effect of hepatitis B virus (HBV)-active antiretroviral therapy against HBV infection.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:2

    Topics: Adenine; Animals; Antiviral Agents; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Mice; Organo

2015
The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2014, Volume: 25, Issue:6

    Topics: Adenine; Antiviral Agents; End Stage Liver Disease; Female; Hepatitis B; Humans; Immunoglobulins; Li

2014
[Case report; A case of Fanconi's syndrome with pathological ulnar fractures improved by dose reduction of adefovir and supplementation of oral phosphate].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Aug-10, Volume: 103, Issue:8

    Topics: Adenine; Administration, Oral; Aged; Antiviral Agents; Fanconi Syndrome; Female; Fractures, Spontane

2014
Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Transplant infectious disease : an official journal of the Transplantation Society, 2015, Volume: 17, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Viral;

2015
Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
    Journal of medical virology, 2015, Volume: 87, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanin

2015
Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
    Transplantation proceedings, 2015, Volume: 47, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Female; Graft Survival; G

2015
Relationship Between Serum DNA Replication, Clinicopathological Characteristics and Prognosis of Hepatitis B Virus-associated Glomerulonephritis with Severe Proteinuria by Lamivudine Plus Adefovir Dipivoxil Combination Therapy.
    Biomedical and environmental sciences : BES, 2015, Volume: 28, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA Replication; DNA, Viral; Drug Therapy, Combination; Fema

2015
Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis

2015
A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2015, Volume: 33

    Topics: Adenine; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; Genotype;

2015
Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
    Journal of medical virology, 2015, Volume: 87, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Female; Genetic Variati

2015
Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.
    Antiviral therapy, 2016, Volume: 21, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Child; Codon; DNA, Vira

2016
Tenofovir for Hepatitis Delta.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:4

    Topics: Adenine; Hepatitis B; Hepatitis D; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitor

2016
Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
    Current medicinal chemistry, 2015, Volume: 22, Issue:34

    Topics: Adenine; Adenosine; Amino Acid Sequence; Antiviral Agents; Binding Sites; Catalytic Domain; Database

2015
Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation.
    Medicine, 2015, Volume: 94, Issue:38

    Topics: Adenine; Female; Hepatitis B; Humans; Incidence; Kidney Diseases; Lamivudine; Liver Transplantation;

2015
Occult HBV reactivation induced by ibrutinib treatment: a case report.
    Acta gastro-enterologica Belgica, 2015, Volume: 78, Issue:4

    Topics: Adenine; Aged, 80 and over; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piper

2015
Variability in long-term hepatitis B virus dynamics under antiviral therapy.
    Journal of theoretical biology, 2016, Feb-21, Volume: 391

    Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Hu

2016
[Tetracycline-inducible replications of wild-type and an adefovir-dipivoxil-resistant hepatitis B virus in human liver cells].
    Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2016, Volume: 50, Issue:4

    Topics: Adenine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Genotype; Hepatitis B; Hepatitis B vir

2016
Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:7

    Topics: Adenine; Aged; Antiviral Agents; Cryoglobulinemia; Female; Guanine; Hepatitis B; Hepatitis B e Antig

2016
Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro.
    Antiviral research, 2017, Volume: 139

    Topics: Adenine; Alanine; Antiviral Agents; Drug Resistance, Viral; Genotype; Hep G2 Cells; Hepatitis B; Hep

2017
Severe hepatitis B virus reactivation related to ibrutinib monotherapy.
    Annals of hematology, 2017, Volume: 96, Issue:4

    Topics: Adenine; Aged; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male;

2017
Continuous single motor unit electromyographic activity in adefovir associated myopathy.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2008, Volume: 15, Issue:9

    Topics: Adenine; Antiviral Agents; Chronic Disease; Creatine Kinase; Electromyography; Hepatitis B; Humans;

2008
Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; Bilirubin; Disease Progression; Drug Resistance, Viral; Female; Fo

2008
Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients.
    Transplantation, 2008, Aug-27, Volume: 86, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B; Hepatitis B Surface

2008
Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers.
    European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Carrier State; Drug Therapy, Combination; Hepatitis B; Hepatitis B

2008
Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance.
    Journal of hepatology, 2009, Volume: 50, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA Probes; DNA, Viral; Drug Resistance, Viral; Female; Guanine; H

2009
Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
    HIV medicine, 2009, Volume: 10, Issue:4

    Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cross-Sectional Studi

2009
Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy.
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Female; Hepatitis B;

2009
Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
    HIV medicine, 2009, Volume: 10, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, C

2009
Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients.
    World journal of gastroenterology, 2009, Feb-14, Volume: 15, Issue:6

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Genetic Variation

2009
The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:4

    Topics: Adenine; Anti-HIV Agents; Cell Line, Tumor; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Gua

2009
Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.
    Iranian journal of immunology : IJI, 2009, Volume: 6, Issue:1

    Topics: Adenine; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antiviral Agents; Behcet Syndrome;

2009
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
    The Journal of infectious diseases, 2009, May-01, Volume: 199, Issue:9

    Topics: Adenine; Antiviral Agents; Base Sequence; DNA Primers; DNA, Viral; Drug Resistance, Viral; Genetic V

2009
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
    The New England journal of medicine, 2009, Apr-30, Volume: 360, Issue:18

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepa

2009
Emergency transplantation for acute reactivation of chronic hepatitis B with high viral load: role of antiviral therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:5

    Topics: Adenine; Blood Chemical Analysis; DNA, Viral; Hepatitis B; Humans; Immunoglobulins; Lamivudine; Live

2009
Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:7

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Female

2009
[Failure to treat hepatitis B virus infection with adefovir due to early selection of rtA181T mutation].
    Medicina clinica, 2010, Apr-10, Volume: 134, Issue:10

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B Antige

2010
Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay.
    Clinica chimica acta; international journal of clinical chemistry, 2009, Volume: 408, Issue:1-2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; Humans; Ligases;

2009
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
    HIV medicine, 2010, Volume: 11, Issue:1

    Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Anti-Retroviral Agents; Cameroon; Comorbidity; Female;

2010
Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus.
    Journal of viral hepatitis, 2010, Feb-01, Volume: 17, Issue:2

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Resistanc

2010
Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy.
    Transplant infectious disease : an official journal of the Transplantation Society, 2009, Volume: 11, Issue:6

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; Humans

2009
The significance of enzyme immunoassay for the assessment of hepatitis B virus core-related antigen following liver transplantation.
    Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:18

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B Core Antigens;

2009
[Tenofovir, An antiviral agent with activity against HIV infections and hepatitis B].
    Revue de l'infirmiere, 2009, Issue:153

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Hepatitis B; Hepatitis B virus; Humans; Organophosphonat

2009
Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir.
    Antiviral therapy, 2009, Volume: 14, Issue:6

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Human

2009
Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 47, Issue:1

    Topics: Adenine; Antibodies, Viral; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination;

2010
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:1

    Topics: Adenine; Adolescent; Adult; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B

2010
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:1

    Topics: Adenine; Adolescent; Adult; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B

2010
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:1

    Topics: Adenine; Adolescent; Adult; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B

2010
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:1

    Topics: Adenine; Adolescent; Adult; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B

2010
[Protocol for the antiviral therapy of hepatitis B and D].
    Orvosi hetilap, 2010, Jan-03, Volume: 151, Issue:1

    Topics: Adenine; Antiviral Agents; Biopsy; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface

2010
[The antiviral treatment impacts on clinical outcomes of renal transplantation recipients with hepatitis B virus infection].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2009, Volume: 23, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; Case-Control Studies; Female; Hepatitis B; Hepatitis B virus

2009
Liver transplantation in bearers of hepatitis B associated or not with delta hepatitis in the age of the new antiviral drugs: is hyperimmune globulin still necessary?
    Transplantation proceedings, 2010, Volume: 42, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Aspartate Aminotransferases; Female; Guanine; Hepatitis B; H

2010
Viral resistance in hepatitis B: prevalence and management.
    Current gastroenterology reports, 2010, Volume: 12, Issue:1

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genetic Testing; Genotype; Guanine; Hepatitis B;

2010
Peptide nucleic acid array for detection of point mutations in hepatitis B virus associated with antiviral resistance.
    Journal of clinical microbiology, 2010, Volume: 48, Issue:9

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B; Hepatitis B vir

2010
Acute hepatitis B infection associated with drug-resistant hepatitis B virus.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 48, Issue:4

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral

2010
Drug therapy: tenofovir.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:2

    Topics: Adenine; Antiviral Agents; Female; Hepatitis B; Humans; Middle Aged; Organophosphonates; Tenofovir

2010
Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Asian People; DNA, Circular; DNA, Viral; Drug Resistance; Fe

2011
High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
    Journal of medical virology, 2010, Volume: 82, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Comorbidity; Cross-S

2010
[Resistance mutation patterns of hepatitis B virus in patients with suboptimal response to adefovir dipivoxil therapy after lamivudine resistance].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2010, Volume: 18, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; Hu

2010
Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients.
    Journal of clinical microbiology, 2010, Volume: 48, Issue:12

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Asian People; China; Drug Resistance, Viral; Female; G

2010
A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads.
    Bioinformatics (Oxford, England), 2010, Dec-01, Volume: 26, Issue:23

    Topics: Adenine; Algorithms; Classification; DNA Mutational Analysis; Drug Resistance, Viral; Guanine; Hepat

2010
Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant.
    Transplantation proceedings, 2010, Volume: 42, Issue:8

    Topics: Adenine; Adult; Aged; Antiviral Agents; Combined Modality Therapy; Female; Guanine; Hepatitis B; Hum

2010
Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus (J Viral Hepat 2010 Feb 1;17(2):123-9).
    Journal of viral hepatitis, 2011, Volume: 18, Issue:11

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; Humans; K

2011
Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.
    World journal of gastroenterology, 2010, Nov-21, Volume: 16, Issue:43

    Topics: Adenine; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B; Hepatitis

2010
Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Transplant infectious disease : an official journal of the Transplantation Society, 2011, Volume: 13, Issue:3

    Topics: Adenine; Antiviral Agents; Combined Modality Therapy; Drug Resistance, Viral; Guanine; Hepatitis B;

2011
Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation.
    Minerva medica, 2010, Volume: 101, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B; Hepatitis

2010
Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs.
    Scandinavian journal of gastroenterology, 2011, Volume: 46, Issue:6

    Topics: Adenine; Adult; Elasticity Imaging Techniques; Female; Hepatitis B; Humans; Lamivudine; Liver; Liver

2011
[The replication capacity and drug sensitivity of Adefovir dipivoxil-resistant HBV mutants in vivo].
    Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2011, Volume: 28, Issue:1

    Topics: Adenine; Animals; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Hepatitis B; Hepatitis B

2011
Successful tenofovir treatment for fulminant hepatitis B infection in an infant.
    The Pediatric infectious disease journal, 2011, Volume: 30, Issue:10

    Topics: Adenine; Antiviral Agents; Female; Hepatitis B; Humans; Infant; Organophosphonates; Tenofovir; Treat

2011
Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection.
    Clinical and experimental nephrology, 2011, Volume: 15, Issue:5

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine

2011
Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy.
    Transplant infectious disease : an official journal of the Transplantation Society, 2012, Volume: 14, Issue:1

    Topics: Adenine; Age of Onset; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hematopoietic S

2012
Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.
    Journal of medicinal chemistry, 2011, Aug-25, Volume: 54, Issue:16

    Topics: Adenine; Animals; Antiviral Agents; Biological Availability; Drug Design; Drug Resistance, Viral; Gu

2011
HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2011, Volume: 52, Issue:3

    Topics: Adenine; Antiviral Agents; Coinfection; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepati

2011
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Dr

2012
Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
    Clinical and vaccine immunology : CVI, 2012, Volume: 19, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; Female; Genotype; Hepatitis B; H

2012
Synthesis, anti-HBV activity and renal cell toxicity evaluation of mixed phosphonate prodrugs of adefovir.
    European journal of medicinal chemistry, 2012, Volume: 49

    Topics: Adenine; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cell Line; Cell Survival; Hep G2

2012
Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Emtricitabine; Female; Hepatitis B; Humans; Immunog

2012
Severe vitamin D deficiency in a patient treated for hepatitis B with tenofovir.
    International journal of STD & AIDS, 2012, Volume: 23, Issue:1

    Topics: Adenine; Hepatitis B; Humans; Hypophosphatemia; Male; Middle Aged; Organophosphonates; Reverse Trans

2012
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
    Orvosi hetilap, 2012, Mar-11, Volume: 153, Issue:10

    Topics: Adenine; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combi

2012
Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:7

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Femal

2012
[Prognosis analysis of hepatitis B virus recurrence after liver transplantation: a single-center study of 38 cases].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:1

    Topics: Adenine; Adult; Female; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Transplantation; M

2012
Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:9

    Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Drug Administration Routes; Female; Hepatiti

2012
Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2012, Volume: 14, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Fem

2012
Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry.
    Journal of hepatology, 2012, Volume: 57, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Congenital Abnormalities; Female; Hepatitis B; Hepatitis B virus;

2012
Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
    The Journal of infectious diseases, 2012, Sep-15, Volume: 206, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Administra

2012
Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a New York City AIDS center.
    Journal of Korean medical science, 2012, Volume: 27, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B; Hepatitis B e Antigens; HIV Infec

2012
Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.
    Antiviral therapy, 2012, Volume: 17, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cloning, Molecular; DNA, Viral; Drug Resistance, Viral; Drug

2012
Prolonged adefovir therapy associated Fanconi syndrome and interstitial nephritis in hepatitis B.
    Internal medicine journal, 2012, Volume: 42, Issue:8

    Topics: Adenine; Drug Administration Schedule; Fanconi Syndrome; Hepatitis B; Humans; Male; Middle Aged; Nep

2012
Does genotype predict response to treatment in children infected with hepatitis B perinatally?
    Journal of medical virology, 2012, Volume: 84, Issue:10

    Topics: Adenine; Adolescent; Anti-Inflammatory Agents; Antiviral Agents; Child; Child, Preschool; Clinical T

2012
Does interferon-sparing tenofovir disoproxil fumarate-based therapy have a role in the management of severe acute hepatitis delta superinfection?
    Journal of medical microbiology, 2012, Volume: 61, Issue:Pt 12

    Topics: Acute Disease; Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepati

2012
Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:12

    Topics: Adenine; Animals; Antiviral Agents; Cell Line; Deoxycytidine; Drug Combinations; Drug Interactions;

2012
Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States.
    Journal of hepatology, 2013, Volume: 58, Issue:2

    Topics: Acute Disease; Adenine; Adult; Antiviral Agents; Cohort Studies; Cross-Sectional Studies; Drug Resis

2013
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:11

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Deoxycytid

2012
Blunted fetal growth by tenofovir in late pregnancy.
    AIDS (London, England), 2012, Oct-23, Volume: 26, Issue:16

    Topics: Adenine; Adult; Anti-HIV Agents; Asian People; Bone Density; Female; Fetal Growth Retardation; Hepat

2012
Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene.
    Journal of medical virology, 2013, Volume: 85, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B; Hepatitis B An

2013
Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies.
    Acta pharmacologica Sinica, 2013, Volume: 34, Issue:2

    Topics: Adenine; Amino Acid Sequence; Antiviral Agents; DNA-Directed DNA Polymerase; Genotype; Hepatitis B;

2013
The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir.
    Antiviral research, 2013, Volume: 97, Issue:2

    Topics: Adenine; Amino Acid Substitution; Animals; Antiviral Agents; Computational Biology; Disease Models,

2013
Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
    Journal of medical virology, 2013, Volume: 85, Issue:4

    Topics: Adenine; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; DNA,

2013
Sexually transmitted infection with an immune-escape mutant hepatitis B virus in an hepatitis B virus-vaccinated individual with acute HIV-hepatitis C virus infection.
    AIDS (London, England), 2013, Feb-20, Volume: 27, Issue:4

    Topics: Acute Disease; Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Deoxycytidine; Drug

2013
Efficacy of combined antiviral therapy with lamivudine and tenofovir in a liver transplanted girl with de novo hepatitis B virus infection.
    Transplant infectious disease : an official journal of the Transplantation Society, 2013, Volume: 15, Issue:2

    Topics: Adenine; Antiviral Agents; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis B; Hepatit

2013
Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:2

    Topics: Adenine; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Mutation; Organ

2002
Treatment of recurrent hepatitis B infection in liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2002, Volume: 8, Issue:10 Suppl 1

    Topics: 2-Aminopurine; Adenine; Antiviral Agents; Famciclovir; Hepatitis B; Humans; Interferon-alpha; Lamivu

2002
Editorial comment: a tale of two viruses.
    The AIDS reader, 2002, Volume: 12, Issue:10

    Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Vaccines; HIV I

2002
FDA recommends hepatitis B drug.
    AIDS patient care and STDs, 2002, Volume: 16, Issue:10

    Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Approval; Hepatitis B; Humans; Kidney

2002
Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
    The New England journal of medicine, 2003, Jan-09, Volume: 348, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; He

2003
Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2003, Volume: 9, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Bacterial Infections; Cholestasis; Drug Resistance, Microbial; Fib

2003
Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
    Gastroenterology, 2003, Volume: 124, Issue:2

    Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Hepatitis B; Hepatitis B virus; Humans; Lamiv

2003
Tenofovir helps beat hepatitis B.
    TreatmentUpdate, 2003, Volume: 15, Issue:1

    Topics: Adenine; Antiviral Agents; CD4 Lymphocyte Count; Hepatitis B; Hepatitis B virus; HIV; HIV Infections

2003
Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA.
    Gastroenterology, 2003, Volume: 125, Issue:1

    Topics: Adenine; Animals; Capsid; Combined Modality Therapy; Disease Models, Animal; Gene Expression Regulat

2003
Antiviral Research--16th Annual International Conference. Satellite symposium: clinical update on antiviral drugs. 27 April-1 May 2003, Savannah, GA, USA.
    IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:6

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Enfuvirtide; Ganciclovir; Hepa

2003
Recent studies of adefovir dipivoxil for hepatitis B.
    Journal of pediatric gastroenterology and nutrition, 2003, Volume: 37, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Child; Controlled Clinical Trials as Topic; Hepatitis B; Hepatitis

2003
Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure.
    Transplantation, 2003, Oct-27, Volume: 76, Issue:8

    Topics: Acute Disease; Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Graft Surviv

2003
Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation.
    Transplantation, 2004, Feb-15, Volume: 77, Issue:3

    Topics: Acute Disease; Adenine; Antiviral Agents; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface A

2004
Antiretroviral therapy and HIV/hepatitis B virus coinfection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Mar-01, Volume: 38 Suppl 2

    Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis B virus; HI

2004
[Viral hepatitis B/C and HIV. Therapy of double infections].
    MMW Fortschritte der Medizin, 2003, Apr-28, Volume: 145 Spec No 1

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as T

2003
Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2004, Volume: 10, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Cholestasis, Intrahepatic; Drug Resistance, Viral; Drug Therapy, C

2004
Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains.
    Digestive diseases and sciences, 2004, Volume: 49, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance; Hepatitis B; Hepatitis B virus; Humans; Lami

2004
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Antiviral therapy, 2004, Volume: 9, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Cell Line; DNA-Directed DNA Polymerase; DNA, Viral; Dose-Response

2004
A novel pattern (sW195a) in surface gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during lamivudine therapy and successful treatment with adefovir dipivoxil.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2004, Volume: 31, Issue:1

    Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Hepatitis B; Hepatitis B

2004
Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model.
    Antiviral research, 2004, Volume: 63, Issue:2

    Topics: Adenine; Administration, Oral; Amino Acid Motifs; Amino Acid Substitution; Animals; Antiviral Agents

2004
Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Carrier State; Drug Resistance; Female; Hepatitis B; Humans; Lamiv

2004
Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2004, Volume: 10, Issue:11

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Graft Survival; Hepatitis B;

2004
Tenofovir therapy for lamivudine resistance following liver transplantation.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B,

2004
Intramolecular stacking interactions in ternary copper(II) complexes formed by a heteroaromatic amine and 9-[2-(2-phosphonoethoxy)ethyl]adenine, a relative of the antiviral nucleotide analogue 9-[2-(phosphonomethoxy)ethyl]adenine.
    Journal of inorganic biochemistry, 2004, Volume: 98, Issue:12

    Topics: Adenine; Amines; Anions; Antiviral Agents; Chelating Agents; Copper; Hepatitis B; Hydrogen-Ion Conce

2004
Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant.
    Transplantation proceedings, 2004, Volume: 36, Issue:8

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Resistance; Follow-Up Studies; Hepat

2004
Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.
    Intervirology, 2004, Volume: 47, Issue:6

    Topics: Adenine; Adult; Alanine Transaminase; Drug Resistance, Microbial; Female; Genotype; Hepatitis B; Hep

2004
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
    AIDS (London, England), 2004, Nov-19, Volume: 18, Issue:17

    Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Chronic Disease; DNA-Directe

2004
Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin.
    Transplantation proceedings, 2004, Volume: 36, Issue:9

    Topics: Adenine; Adult; Antibodies, Viral; Antiviral Agents; Drug Resistance; Female; Hepatitis B; Hepatitis

2004
Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection.
    The New England journal of medicine, 2005, Jan-20, Volume: 352, Issue:3

    Topics: Acute Disease; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Hepa

2005
Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection.
    Transplantation proceedings, 2005, Volume: 37, Issue:3

    Topics: Adenine; Antiviral Agents; Creatinine; Drug Resistance, Viral; Follow-Up Studies; Hepatitis B; Human

2005
Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus.
    Transplantation proceedings, 2005, Volume: 37, Issue:3

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B; Hepatitis B

2005
Tenofovir helpful for patients with HBV.
    AIDS patient care and STDs, 2005, Volume: 19, Issue:5

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B; HIV Infections; Humans

2005
Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results.
    Transplant international : official journal of the European Society for Organ Transplantation, 2005, Volume: 18, Issue:7

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hep

2005
Reactivation of viral replication after replacement of tenofovir by adefovir.
    Hepatology (Baltimore, Md.), 2005, Volume: 42, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Hepatitis B; Humans; Male; Middle Aged; Organophosphonates; Tenofo

2005
The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients.
    Journal of hepatology, 2005, Volume: 43, Issue:2

    Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans;

2005
[Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease].
    The Korean journal of hepatology, 2005, Volume: 11, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Humans; Lamivud

2005
Association of polymorphism of tumor necrosis factor-alpha gene promoter region with outcome of hepatitis B virus infection.
    World journal of gastroenterology, 2005, Sep-07, Volume: 11, Issue:33

    Topics: Adenine; Adult; Case-Control Studies; Cytosine; Female; Genotype; Hepatitis B; Hepatitis B virus; He

2005
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.
    Journal of hepatology, 2005, Volume: 43, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Disease Progression; Drug Resistance, Viral; Hepatitis B; He

2005
Community-based epidemiology of hepatitis B virus infection in West Bengal, India: prevalence of hepatitis B e antigen-negative infection and associated viral variants.
    Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:11

    Topics: Adenine; Adolescent; Adult; Child; Codon, Terminator; Demography; DNA, Viral; Genetic Variation; Gen

2005
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2006, Volume: 35, Issue:4

    Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplas

2006
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
    Hepatology (Baltimore, Md.), 2005, Volume: 42, Issue:6

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Fe

2005
Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.
    Transplantation proceedings, 2005, Volume: 37, Issue:9

    Topics: Adenine; Alanine Transaminase; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B e Antigens;

2005
Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2006, Volume: 36, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Hepatitis B;

2006
Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation.
    Bone marrow transplantation, 2006, Volume: 37, Issue:6

    Topics: Adenine; Adult; Antineoplastic Agents; Combined Modality Therapy; Female; Hepatitis B; Hepatitis B v

2006
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
    Hepatology (Baltimore, Md.), 2006, Volume: 43, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy,

2006
Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2006, Volume: 12, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Health Car

2006
[Reactivation of hepatitis B treated with adefovir after infliximab administration].
    Medicina clinica, 2006, Apr-15, Volume: 126, Issue:14

    Topics: Adenine; Antibodies, Monoclonal; Antiviral Agents; Hepatitis B; Humans; Immunosuppressive Agents; In

2006
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:2

    Topics: Adenine; Adult; Disease Progression; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies;

2006
Favorable outcome of liver transplantation despite a high hepatitis B virus replication: beyond the limits?
    Transplant infectious disease : an official journal of the Transplantation Society, 2006, Volume: 8, Issue:3

    Topics: Adenine; Antiviral Agents; Contraindications; Hepatitis B; Humans; Liver Transplantation; Male; Midd

2006
Hepatitis delta virus super-infection in a co-infected patient with the human immunodeficiency virus type 1 and a surface antigen-negative hepatitis B virus variant.
    International journal of STD & AIDS, 2006, Volume: 17, Issue:9

    Topics: Adenine; Alanine Transaminase; Amino Acid Sequence; Anti-HIV Agents; Follow-Up Studies; Hepatitis B;

2006
Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
    Antiviral therapy, 2006, Volume: 11, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy,

2006
Nonresponse to adefovir: host or virus dependent?
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2006, Volume: 37, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Humans; Organophosphonates

2006
Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results.
    Transplantation proceedings, 2006, Volume: 38, Issue:9

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Follow-Up Studi

2006
Successful treatment with adefovir of one patient whose cryoglobulinemic vasculitis relapsed under lamivudine therapy and who was diagnosed to have HBV virologic breakthrough with YMDD mutations.
    Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:21

    Topics: Adenine; Amino Acid Motifs; Aspartic Acid; Cryoglobulinemia; Female; Hepatitis B; Hepatitis B virus;

2006
Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs.
    AIDS patient care and STDs, 2006, Volume: 20, Issue:12

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; DNA, Viral; Female; Hepatitis B; HIV Infectio

2006
[Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation].
    Gastroenterologie clinique et biologique, 2007, Volume: 31, Issue:1

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Hematopoietic Stem Cell T

2007
Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2007, Volume: 13, Issue:3

    Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; H

2007
Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:10

    Topics: Adenine; Adult; Aged; Antibodies, Viral; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Fe

2007
Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.
    AIDS (London, England), 2007, Mar-30, Volume: 21, Issue:6

    Topics: Adenine; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Organophosphona

2007
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
    Antiviral therapy, 2007, Volume: 12, Issue:1

    Topics: Adenine; CD4 Lymphocyte Count; DNA, Viral; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; H

2007
Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:2

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Vi

2007
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
    Antiviral therapy, 2007, Volume: 12, Issue:3

    Topics: Adenine; Antiviral Agents; Cell Line, Tumor; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistanc

2007
Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:10

    Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Cell Line; Female; Hepatitis B; Hepatitis B vir

2007
Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials.
    Journal of hepatology, 2007, Volume: 47, Issue:4

    Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Clinical Trials as Topic; DNA Mutational Analysi

2007
Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
    Journal of medical virology, 2007, Volume: 79, Issue:10

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomar

2007
Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
    Chinese medical journal, 2007, Aug-20, Volume: 120, Issue:16

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Hepatit

2007
[New German and American guidelines for therapy of hepatitis B. Discrepancies and similarities].
    Medizinische Klinik (Munich, Germany : 1983), 2007, Sep-15, Volume: 102, Issue:9

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Drug Th

2007
Development of a novel mouse model to evaluate drug candidates against hepatitis B virus.
    Antiviral chemistry & chemotherapy, 2007, Volume: 18, Issue:4

    Topics: Adenine; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Drug Evaluation, Preclinical;

2007
Successful treatment of an entecavir-resistant hepatitis B virus variant.
    Journal of medical virology, 2007, Volume: 79, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Fe

2007
Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years.
    Liver international : official journal of the International Association for the Study of the Liver, 2008, Volume: 28, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepatitis B; Hepatitis B

2008
Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus;

2007
Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
    Journal of hepatology, 2008, Volume: 48, Issue:3

    Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan

2008
[Kinetics of HBV mutants conferring adefovir resistance (rtn236t) and a method to detect them rapidly].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2008, Volume: 16, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus

2008
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.
    Journal of hepatology, 2008, Volume: 48, Issue:5

    Topics: Adenine; Amino Acid Sequence; DNA, Viral; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; Hu

2008
Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Clinical therapeutics, 2008, Volume: 30, Issue:2

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Dr

2008
Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2008, Volume: 14, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Hepatitis

2008
Severe acute pancreatitis related to the use of adefovir in a liver transplant recipient.
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:3

    Topics: Acute Disease; Adenine; Aged; Antiviral Agents; Hepatitis B; Humans; Liver Transplantation; Male; Or

2008
Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study.
    Transplantation, 2008, Apr-27, Volume: 85, Issue:8

    Topics: Adenine; Adult; Aged; Cross-Sectional Studies; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; H

2008
Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:3

    Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Genotype;

2008
[Acute hepatitis B: is antiviral therapy indicated? Two case reports].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:22

    Topics: Acute Disease; Adenine; Adult; Algorithms; Antiviral Agents; Bilirubin; DNA, Viral; Drug Therapy, Co

2008
Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States.
    Gastroenterology, 1993, Volume: 105, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Base Sequence; DNA, Viral; Female; Gene Amplifi

1993
Assessment of peripheral blood mononuclear cell proliferation by [2-3H]adenine uptake in the woodchuck model.
    Clinical immunology and immunopathology, 1996, Volume: 78, Issue:3

    Topics: Adenine; Animals; Animals, Wild; Cell Division; Cells, Cultured; Disease Models, Animal; Hepatitis B

1996
Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G-->A hypermutation.
    Virology, 1997, Aug-18, Volume: 235, Issue:1

    Topics: Adenine; Base Sequence; Carrier State; Dinucleoside Phosphates; DNA Primers; DNA, Viral; Frameshift

1997
Determination of peripheral blood mononuclear cell responses to mitogens and woodchuck hepatitis virus core antigen in woodchucks by 5-bromo-2'-deoxyuridine or 2[3H]adenine incorporation.
    Archives of virology, 1997, Volume: 142, Issue:3

    Topics: Adenine; Animals; Bromodeoxyuridine; Cell Division; Concanavalin A; DNA; Hepatitis B; Hepatitis B Co

1997
Evaluation of anti-hepatitis B virus (HBV) drugs using the HBV transgenic mouse: application of the semiquantitative polymerase chain reaction (PCR) for serum HBV DNA to monitor the drug efficacy.
    Biochemical and biophysical research communications, 1997, Dec-08, Volume: 241, Issue:1

    Topics: Adenine; Animals; Antiviral Agents; DNA Replication; DNA, Viral; Drug Monitoring; Hepatitis B; Hepat

1997
Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients.
    Cancer, 1998, Oct-15, Volume: 83, Issue:8

    Topics: Adenine; Aged; Carcinoma, Hepatocellular; Codon; Cohort Studies; DNA, Viral; Exons; Female; Genes, p

1998
Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin.
    Transplantation, 1999, Dec-27, Volume: 68, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Carrier State; DNA-Directed DNA Polymerase; Drug Resistance; Femal

1999
Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:3

    Topics: Adenine; Animals; Antiviral Agents; Chromatography; Drug Carriers; Hepatitis B; Lipoproteins, HDL; L

2000
Incidental treatment of hepatitis B virus infection in an AIDS patient.
    The AIDS reader, 2000, Volume: 10, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy,

2000
Mechanistic study on the cytostatic and tumor cell differentiation-inducing properties of 9-(2-phosphonylmethoxyethyl)adenine (PMEA, adefovir)-collected publications.
    Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie, 2000, Volume: 62, Issue:5

    Topics: Adenine; Animals; Antineoplastic Agents; Antiviral Agents; Cell Differentiation; Cell Division; Cell

2000
[Current treatment of hepatitis B].
    Gastroenterologia y hepatologia, 2001, Volume: 24 Suppl 1

    Topics: 2-Aminopurine; Adenine; Anti-Inflammatory Agents; Antiviral Agents; DNA Replication; Famciclovir; Fo

2001
Adefovir dipivoxil (Preveon) new results with hepatitis B, HIV.
    AIDS treatment news, 1998, Apr-17, Issue:No 293

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Dru

1998
Preveon expanded access program broadened.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1998

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis B; HIV Infections;

1998
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra

2001
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra

2001
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra

2001
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra

2001
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra

2001
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra

2001
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra

2001
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra

2001
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra

2001
Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:10

    Topics: Adenine; Administration, Oral; Animals; Chemistry, Clinical; Chronic Disease; Disease Models, Animal

2001
Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:2

    Topics: Adenine; Animals; Antiviral Agents; Disease Models, Animal; DNA, Circular; DNA, Viral; Ducks; Hepati

2002
Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus.
    Antiviral research, 2002, Volume: 55, Issue:1

    Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Disease Models, Animal; DNA, Viral; Dose-R

2002